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ABSTRACT 
 
Purpose: The purpose of this study was to examine the effects of a chemically 
modified resistant starch, RS4, on diarrhea and inflammation induced by Citrobacter 
rodentium. We hypothesized that a diet supplemented with RS4, contributing to 
25% resistance of the total starch in the diet (55% starch diet), would significantly 
improve stool consistency and provide protection against the inflammation 
associated with the pathogen, including inflammation score, mucosal height, 
ulceration, goblet cell loss, edema, and hyperplasia.  
 
Design: 36 mice (18 male, and 18 female) were randomly assigned four treatment 
groups: uninfected mice fed the control starch diet, uninfected mice fed the RS4 
supplemented diet, C. rodentium infected mice fed the control starch diet, and C. 
rodentium infected mice fed the RS4 supplemented diet. After inoculation with C. 
rodentium, mice were be subjected to the diets for two weeks, and daily food intake, 
body weight, and stool consistency were measured. At the completion of the two 
weeks, mice were euthanized and blood was collected via cardiac puncture for 
serum glucose, insulin, and lipid analysis. Colon and cecum contents were collected 
and analyzed for pH, stool fat, and water content; and the tissues were sent for 
histopathology scoring.  
iv 
Expected results: C. rodentium infected mice fed the RS4 supplemented diet were 
expected to show a significant increase in stool consistency compared to the 
infected mice the fed the control starch diet. The infected mice fed the RS4 diet were 
also expected to have a less severe inflammatory response due to the C. rodentium 
compared to the infected mice fed the control diet, which would be seen in the 
histopathology scores. Body weight loss and decreased food intake due to the C. 
rodentium pathogen were expected to be less severe in mice fed the RS4 
supplemented diet, due to its expected protection against inflammation and 
diarrhea. 
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CHAPTER I 
INTRODUCTION: THESIS ORGANIZATION 
 
 This thesis will begin with a review of literature investigating the 
characterization and properties of starch. The review will then concentrate on 
resistant starch, its classification and structure. Methods of measuring resistant 
starch will be mentioned, followed by the effects of resistant starch on the following: 
blood glucose, insulin, cholesterol, triglycerides, short chain fatty acid production, 
satiety and weight maintenance, and diarrhea. Adverse effects of resistant starches 
will be stated, as well as the effects of resistant starch on inflammatory bowel 
disease. The review will then shift focus to Citrobacter rodentium, and its causation 
of diarrheal illness and inflammation in murine models. The review will finish with a 
brief overview of the background, methods, hypotheses and expected results of the 
resistant starch mouse study. Following the review, the materials and methods of 
the study will be presented. The results of the study will be stated, as well as a 
discussion of the findings. This thesis will conclude with references and 
acknowledgements.  
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CHAPTER II 
REVIEW OF LITERATURE 
 
Introduction 
Inflammatory bowel disease, including colitis, is a chronic disease without 
cure. Its trademark symptoms are diarrhea and uncontrollable inflammation of the 
intestinal mucosa. Resistant starch is thought to be beneficial to gut health, through 
its fermentation in the large intestine to create short chain fatty acids. The 
production of short chain fatty acids is thought to improve upon gut barrier 
function, which can be beneficial to diarrheal and colonic diseases. In conjunction 
with the production of short chain fatty acids, resistant starch has a high water 
holding capacity, thought to increase stool bulk and consistency, lessening the 
degree of water in stool. The purpose of this study was to examine the effects of a 
type-4 resistant starch (RS4) on diarrhea and inflammation in C3H mice triggered 
by Citrobacter rodentium, an A/E pathogen that causes inflammation and diarrhea 
similar to that of colitis. It was hypothesized that a diet supplemented with RS4 
would primarily increase stool consistency in mice inoculated with C. rodentium. 
The RS4 diet treatment would also cause mice to experience a less severe 
inflammatory response due to the C. rodentium, which include goblet cell loss, 
mucosal height elevation, hyperplasia, edemas, and ulceration.  
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Starch Characterization 
 
Starch is one of the main forms of dietary carbohydrates in humans, and 
contributes to more than 50% of daily energy intake in humans (Topping, 
Fukushima et al. 2003). In higher plants, starch is synthesized in plastids, and 
degraded at night to provide substrates for leaf respiration and sucrose synthesis. In 
tubers, roots and other non-photosynthetic organs, sucrose is converted to starch 
for long-term storage (Zeeman, Kossmann et al. 2010). 
Chemically, starches are polysaccharides with α-1,4 and/or α-1,6 linkages 
between monosaccharides. Two main structural types of starch exist, amylose and 
amylopectin. Amylose is a relatively small, linear, and consists of α-1,4 linkages 
(Bird, Brown et al. 2000, Hoover 2000, Nugent 2005, Englyst, Liu et al. 2007). Due to 
the linearity of the molecule, amylose is associated with a lessened degree of 
digestibility compared to amylopectin (Nugent 2005). Amylopectin is a branched 
molecule with both types of linkages, which contribute to its larger size compared to 
amylose (Bird, Brown et al. 2000, Nugent 2005). Most commercially available 
starches have 70-80% amylopectin (Bird, Brown et al. 2000). 
Amylose and amylopectin form semi crystalline granules, with two main 
types. A type is found in cereals and B type is found in tubers and amylose-rich 
starches. A third crystalline type has been found, C type, and is a mixture of A and B 
types. C type crystalline structure is primarily found in legumes (Tester, Karkalas et 
al. 2004, Nugent 2005, Zeeman, Kossmann et al. 2010). 
Starches are broken down first through hydrolysis by salivary α-amylases 
into shorter oligosaccharides. Once the partially digested starch is sent to the gut, 
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where the pancreatic α-amylases hydrolyze to cleave α-1,4 linkages at random 
locations. Brush border enzymes convert the products to free glucose.  Overall, 
hydrolysis of starches yields free glucose that can be absorbed and distributed 
throughout the body (Asp, Van Amelsvoort et al. 1996, Nugent 2005, Lehmann and 
Robin 2007). Cooking starches with excess water, also known as gelatinization, can 
increase the degree of hydrolysis (Bird, Brown et al. 2000). 
Starch can be divided into different subcategories based upon digestibility, or 
breakdown by enzymes: rapidly digestible starch, slowly digestible starch, and 
resistant starch. Rapidly digestible starch, RDS, is found mostly in starches cooked in 
moist heat. This can include bread or potatoes. RDS is converted to glucose within 
20 minutes of enzyme digestion in the small intestine. Slowly digestible starch, SDS, 
consists of type A and C crystalline structure. SDS is completely digested in the small 
intestine, but at a slower rate than RDS, and is digested within 20-120 minutes. 
Resistant starch, RS, has a slowed or no hydrolysis by α –amylase, so that part of the 
starch reaches the large intestine. The RS value is the difference between what the 
total starch and the amount of starch hydrolyzed by 120 minutes (Englyst and 
Hudson 1996, Sajilata, Singhal et al. 2006). 
 
Resistant Starch Classification and Structure 
Resistant starch can be defined as any starch that resists digestion in the 
small intestine, and passes to the large intestine where it is subjected to 
fermentation (Englyst and Hudson 1996, Nugent 2005). Fermentation of starch in 
the large intestine yields end products such as hydrogen, carbon dioxide, methane, 
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and short chain fatty acids (Ferguson, Tasman-Jones et al. 2000, Nugent 2005). The 
resistance of starch is associated with the interaction between the starch polymers. 
Due to the lack of branching, amylose is associated with a slower digestion. B and C 
crystal types are also associated with a lesser degree of digestibility (Nugent 2005). 
Resistant starches can be separated into four subtypes based upon degree of 
physical inaccessibility, granular structure, degree of retrogradation, amylose-
amylopectin ratio, and chemical modifications. These subtypes include: RS1, RS2, 
RS3, and RS4 (Bird, Brown et al. 2000, Nugent 2005, Englyst, Liu et al. 2007). 
RS1 starches are physically inaccessible to digestion (Nugent 2005, Sajilata, 
Singhal et al. 2006). The inaccessibility is due to intact cell walls, which would be 
seen in grains, seeds and tubers. RS1 starches are heat stable, which is what allows 
them to be a useful food ingredient. Milling or chewing can help increase 
digestibility of this type of starch (Bird, Brown et al. 2000, Nugent 2005). Large 
particles transport more quickly through the gut, with less absorption by the small 
intestine. Smaller particles would have more absorption in the intestine, with 
significantly smaller amounts arriving at the large intestine (Topping, Fukushima et 
al. 2003). 
RS2 describes starches in their native granule form. The structure of the 
granule is the property that protects the starches from digestion (Bird, Brown et al. 
2000, Nugent 2005). The granule is tightly packed, leaving it somewhat dehydrated. 
The compact structures of the granules permit the starch to be partially inaccessible 
to digestive enzymes (Haralampu 2000, Sajilata, Singhal et al. 2006). A high amylose 
to amylopectin ratio is present in RS2 starches, and the most commonly used RS2s 
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are high-amylose starches (Bird, Brown et al. 2000). Foods that contain RS2 include 
raw potatoes and green bananas.  A large benefit to RS2 in the food industry is that 
it retains its structure and resistance even during food preparation and processing 
(Nugent 2005). 
RS3 is associated with non-granular starches formed during the 
retrogradation of starch granules. RS3 starches are characterized by their high 
thermal stability. Retrogradation occurs when starch is cooked past its 
gelatinization temperature, then cooled. The heating in excess water, or the 
gelatinization, disrupts the starch granules. Once in the gelatinization phase, the 
starch is accessible to digestive enzymes. In retrogradation, however, the starches 
are re-cooled. The cooling period forces the unstable starches to re-crystallize, and 
the new crystal structures are resistant to amylase hydrolysis (Haralampu 2000, 
Nugent 2005). Cooked and cooled potatoes are a prime instance of RS3 (Sajilata, 
Singhal et al. 2006). 
RS4 designates chemically or physically modified starches. Chemical 
modification of RS4 consists of incorporation of different substituents on starch 
chains (Bronkowska, Orzel et al. 2013). Types of modification include esterification, 
etherification, and cross bonding (Nugent 2005). Resistance of RS4 starches 
increases with increasing substitution or chemical modifications. These 
modifications can hinder the interaction between enzyme and starch due to the 
compositional and structural changes made to the starch (Leszczynski 2004, 
Bronkowska, Orzel et al. 2013). 
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Effects that can alter or inhibit amylase activity can also disturb digestibility. 
Ways to alter amylase activity include the formation of amylose-lipid complexes and 
the incidence α-amylase inhibitors. Degree of chewing and intra-individual 
variations in transit time can also alter digestibility of starches (Nugent 2005). 
 
Table 1. Descriptions and Sources of Resistant Starch 
Type of Resistant Starch Description Sources 
RS1 -Physically inaccessible to 
digestion. 
- Chewing or milling can 
mitigate resistance. 
- Heat Stable. 
- Whole grains. 
- Seeds. 
 
RS2 - Starch in its native 
granular form. 
- Food processing and 
cooking can reduce 
resistance. 
- Ungelatinized. 
- Typically has a high 
amylose level.  
- Raw Potatoes. 
- Green bananas. 
 
RS3 - Retrograted starch.  
- Non-granular starch. 
- Cooked and cooled 
potatoes.  
RS4 - Chemically or physically 
modified. 
- Examples of 
modifications: 
esterification, 
etherification, and cross 
- Food products like breads, 
drinks, and others. 
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Table 1. Descriptions and Sources of Resistant Starch (continued) 
 bonding. 
- Resistance increases 
with increasing chemical 
modifications. 
 
 
 
Resistant Starch: Methods of Measurement 
The Association of Official Analytical Chemists (AOAC) Official Method 
991.43 was used for determining insoluble dietary fiber in the starches, to 
determine the percent resistance.  The benefit to the AOAC 991.43 method is that it 
can directly measure insoluble dietary fiber, which is correlated to the resistant 
starch available in the sample. Thought to mimic human digestion, this method 
provides a sequential enzymatic digestion by a heat stable α-amylase, followed by 
protease, and finally by amyloglucosidase.  
α-amylase is the first subjection to enzymatic hydrolysis to the food or starch 
sample. α-amylase cleaves α-1,4 linkages at random locations. The sample is 
incubated with the amylase for 15 minutes at 100°C. Protease removes any protein 
in the sample through hydrolysis of the peptide bonds in the protein chain. The 
protease stage lasts 30 minutes at 60°C. The solution is next adjusted to a pH of 4.0-
4.7. In starches, it is typically not necessary to change the pH of the solution at this 
step. Amyloglucosidase, the last part of the digestion, is used to cleave the leftover α-
1,6 and end α-1,4 linkages of terminal linkages of amylose and amylopectin. The 
condition is held for 30 minutes at 60°C. The sample is further filtered and the 
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residue is washed with a series of water, ethanol, and acetone, and then vacuum 
dried to yield insoluble dietary fiber. (1992, Zhang, Dhital et al. 2013) 
 
Resistant Starch: Glucose and Insulin Response 
Carbohydrate digestion impacts glucose absorption in the body, and in effect, 
changes the glycemic and insulin response (Brites, Trigo et al. 2011). Since RS 
releases glucose slowly, a portion of glucose escapes the small intestine; it would be 
expected to correlate with less glucose absorption in the organ. This would 
significantly lower insulin response in the body, due to the lessened amount of free 
glucose molecules released from hydrolysis of starch (Asp, Van Amelsvoort et al. 
1996). Along with lowering the glucose response, RS could also help to maintain 
regular glucose levels in the blood, proving to be beneficial to a variety of chronic 
diseases, including diabetes (Brites, Trigo et al. 2011). The metabolism of RS occurs 
five to seven hours after consumption in the ileum and colon, whereas normal 
starch is digested almost straightaway (Fuentes-Zaragoza, Sanchez-Zapata et al. 
2011). A longer digestion time could not only alter glucose response, but also insulin 
response and even satiety.  
Insulin is a hormone that enables glucose uptake in muscle and adipose cells. 
It stimulates the storage of glucose in the form of glycogen by increasing the activity 
of glycogen synthase, the rate-limiting enzyme of glycogen synthesis (Cohen, Nimmo 
et al. 1978). Glucose uptake by cells would cause a decrease of glucose in the blood. 
Insulin plays other roles in the inhibition of the use of stored fat and signaling of 
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hunger and satiety, with a lessened degree of insulin response associated with a 
higher satiety (Holt and Miller 1995, Nugent 2005).  
RS foods are more difficult to digest and in effect release glucose more 
slowly. The outcome of the slowed release of glucose is a lower blood glucose level, 
which in turn lowers insulin response (Nugent 2005, Sajilata, Singhal et al. 2006). 
Other proposals of the affect of RS on glucose include: RS inhibits α-amylase or 
increases the viscosity of stomach and small intestine contents (Ou, Kwok et al. 
2001). 
Raben et al (1994) discovered that after a test meal of RS, no stimulation or a 
modest stimulation of glucose and insulin occurred. Five male subjects were 
subjected to two test meals, consisting of 50g raw potato starch (RS2) or 
pregelatinized potato starch. Subjects experienced a glucose response nine times 
greater with the pregelatinized starch meal than with the RS2 meal. Insulin 
response after the digestible starch meal had increased by a factor of six from 
fasting insulin. A modest increase in insulin response after the RS test meal was 
observed, correlating with the finding that the RS mitigated normal postprandial 
glucose and insulin responses (Raben, Tagliabue et al. 1994). This effect has been 
seen in numerous studies. Robertson et al (2003) demonstrated the acute ingestion 
of a high-RS diet changed insulin sensitivity and clearance in a positive manner 
(Robertson, Currie et al. 2003). Johnston et al (2010), Haub et al (2010), Behall 
(1989), and Nilsson et al (2008) established similar results. Nilsson et al (2007) 
proposed that the glucose and insulin response in a breakfast meal after a RS 
evening meal would be significantly lowered. Fasting blood glucose was not 
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significantly different, but glucose response after the breakfast meal was 
significantly lowered with subjects that had been fed a resistant starch diet the 
evening before (Behall, Scholfield et al. 1989, Nilsson, Ostman et al. 2007, Nilsson, 
Ostman et al. 2008, Haub, Hubach et al. 2010, Johnston, Thomas et al. 2010). 
Similar results have been found in rats. Bronkowska et al (2013) subjected 
Wistar rats to four diets: one control diet containing soybean oil, a second control 
diet containing lard, and two RS supplemented diets with the respective fat sources. 
The study lasted 28 days. Plasma glucose was lower in RS4 fed rats than in their 
perspective control diets (Bronkowska, Orzel et al. 2013). 
However, some studies have found no significant difference in insulin and 
glucose response. In a crossover study, subjects received four meals, only differing 
in RS content, each within a week of one another. The test meals contained from 0% 
to 10.7% RS2, a high amylose starch, as a percentage of total carbohydrate in the 
test meal. There was no difference in postprandial glucose or insulin response for 
any dose of starch examined. Higgins et al (2004), Jenkins et al (1998), and Nestel et 
al (2004) found no change in postprandial insulin and glucose response. This could 
be attributed to fat content of the diet, and source of resistant starch (Jenkins, 
Vuksan et al. 1990, Higgins, Higbee et al. 2004, Nestel, Cehun et al. 2004). Table 2 
summarizes studies that have compared resistant starch to glucose and insulin 
response.  
These studies indicate a lowered glucose and insulin response due to 
consumption of RS (Table 2).   Nilsson et al (2007) did not observe a significantly 
lowered response with RS doses of 11.5g or lower. Further research should be 
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considered to determine a minimum amount of RS to consume long-term to produce 
a significant lowering of glucose and insulin response. Haub et al (2010) observed 
that a RS4 meal contributed to a lower glucose response than that of a RS2 meal, 
both of which were significantly lowered compared to the control. This suggests 
that in humans, different resistant starches elicit different glucose responses. 
Further research is necessary to determine the exact effects of the different RS 
subtypes on glucose response. Overall, these results suggest that long-term and 
short-term intake of RS can improve upon glucose and insulin response. 
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Table 2. Studies of the effects of RS on glucose and insulin. 
Author(s) Subjects Model Design Parameters Measured Results 
Behall, Scholfield et al. 
(1989) 
 
 
Human subjects: 12 
males 
Cross over study. 
Subjects were subjected 
to either 70% amylose 
or 70% amylopectin in 
starch diet, in which 
starch contributed to 
34% of caloric intake, 
for 5 weeks. Fasting 
blood was drawn each 
week, and a glucose 
tolerance test was 
administered after four 
weeks of diet 
consumption. 
Fasting blood was 
analyzed for glucose, 
insulin, triglycerides, 
cholesterol (total and 
HDL), urea nitrogen, and 
uric acid. Postprandial 
plasma was analyzed for 
glucose, insulin, and 
glucagon.  
- No significant 
differences were 
observed for glucose 
and insulin for the 
glucose tolerance test 
following a normal meal. 
- Glucose and insulin 
response were lowered 
for the glucose tolerance 
test after a high amylose 
meal after 5 weeks on 
each starch.   
Haub, Hubach et al. 
(2010) 
Human subjects: 4 male, 
7 female 
Single dose meal 
consisting of 30 g 
carbohydrate or starch.  
Fasting blood glucose, 
and glucose 30, 60, 90, 
and 120 minutes post  
- Peak glucose 
concentration occurred 
at 120 minutes for RS4  
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Table 2. Studies of the effects of RS on glucose and insulin (continued) 
   meal. meal, and at 30 
minutes for dextrose 
and RS2 meal.  
- AUC for glucose 
response was 
significantly lowered in 
RS2 and RS4 meals 
compared to control. 
- AUC for glucose 
response was 
significantly lowered in 
RS4 meal compared to 
RS2 meal. 
Nilsson, Ostman et al. 
(2007) 
Human subjects: 11 
male, 6 female 
Subjects consumed 
evening meals of 
different RS content. 
After a fasting period 
after the evening meal, 
a standardized  
Blood was collected for 
analysis of glucose, 
insulin and various 
other parameters. 
- Fasting blood glucose 
was not significantly 
different between 
evening meal 
treatment.  
- Subjects who  
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Table 2. Studies of the effects of RS on glucose and insulin (continued) 
  breakfast was given to 
subjects. 
 consumed evening 
meals with more than 
11.5 g/serving dietary 
fiber and resistant 
starch exhibited a 
lowered glucose and 
insulin response 
following a 
standardized meal the 
following morning. 
Johnston, Thomas et al. 
(2010) 
Human subjects: 12 
male, 8 female 
Subjects consumed a 
RS  (40g) or placebo 
supplements daily for 
12 weeks.  
Insulin sensitivity was 
measured.  
- Insulin sensitivity 
improved with 
resistant starch 
supplementation 
compared to control.  
Raben, Tagliabue et al. 
(1994) 
Human subjects: 10 
male 
Subjects consumed 
meal with or without 
RS. Meals consisted of 
50 g total starch, where  
Postprandial plasma 
glucose and insulin.  
- Postprandial glucose 
and insulin were 
significantly lower 
after RS meal.  
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Table 2. Studies of the effects of RS on glucose and insulin (continued) 
  RS contributed to 54% 
to the test meal. 
  
Al-Tamimi, Seib et al. 
(2010) 
Human subjects: 6 
male, 7 female 
Subjects consumed a 
dextrose meal bar,  a 
puffed wheat bar (34g), 
or a RS4 bar (34g). 
Blood glucose and 
insulin were measured 
at 10, 20, 30, 60, 90, 
and 120 minutes after 
the meal bar 
consumption. Results 
were reported as AUC. 
- Peak glucose and 
insulin levels were 
significantly lower 
after RS4 treatment 
compared to control 
treatment. 
Bodinham, Frost et al. 
(2010) 
Human subjects: 20 
males 
Subjects consumed 
meals containing 48g 
RS or placebo.  
Postprandial blood 
glucose and insulin 
were measured every 
30 minutes for 7 hours.  
- No significant 
differences were 
observed for blood 
glucose.  
- Postprandial insulin 
was significantly lower 
after the RS meal. 
Bronkowska, Orzel et 
al. (2013) 
Rats: 32 male Wistar Diets contained 33% 
RS4 and had differing 
amounts of fat. Diets  
Blood was collected via 
cardiac puncture for 
determination of  
- The RS4 diets 
demonstrated a 
significantly lowered  
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Table 2. Studies of the effects of RS on glucose and insulin (continued) 
  were fed for 28 days. glucose. glucose results 
compared to the 
control. 
Brites, Trigo et al. 
(2011) 
Rats: 36 male Wistar  Rats were fed breads 
consisting of 20% RS + 
wheat flour, wheat 
flour,  
For the last three days 
of the study, rats were 
tested for postprandial  
- Rats fed the 20% RS + 
wheat flour bread 
displayed a 
significantly  
  20%RS + maize flour, 
or maize flour for 21 
days. 
glucose response. After 
a 12-hour fast, rats 
were fed 2g of diet and 
blood samples were 
taken from the tail vein 
before meal 
consumption, and at 
40, 100, and 160 
minutes after the meal. 
lowered glucose 
response to a meal 
compared to the other 
treatments.  
- No significant 
difference was 
observed for glucose 
response in the 20% 
RS  + maize flour diet. 
Kim, Chung et al. 
(2003) 
Rats: Sprague-Dawley Rats were fed diets 
containing 53% 
cornstarch, 23%  
Fasting plasma glucose 
and insulin were 
measured through  
- No significant 
differences were 
observed in fasting  
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Table 2. Studies of the effects of RS on glucose and insulin (continued) 
  cornstarch + 30% RS 
from corn, or 23% 
cornstarch + 30% RS 
from rice for three 
weeks. 
cardiac puncture after 
euthanasia. 
insulin.  
- There was a tendency 
to decrease blood 
glucose in RS from rice 
diets, however this was 
not significant. 
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Resistant Starch: Cholesterol and Triglycerides 
The liver plays a principal role in the maintenance of cholesterol homeostasis 
in humans. Low-density lipoproteins are taken up by the liver, degraded to bile 
acids, and excreted from the body (Soral-Smietana and Wronkowska 2004). 
Elevated levels of LDL cholesterol is linked with cardiovascular disease risk. 
Elevated triglycerides may be involved in the pathogenesis of atherosclerosis, which 
also increases cardiovascular disease risk (Fernandez, Roy et al. 2000).  
RS can help regulate cholesterol metabolism in the liver by converting higher 
levels of lipids to bile acids for excretion. RS has been thought to reduce LDLs and 
VLDLs in the body (Bronkowska, Orzel et al. 2013). Lower cholesterol levels due to 
RS could be caused by increased bile excretion, lower cholesterol absorption, and 
the synthesis of SCFAs, which in turn lower cholesterol synthesis in the liver 
(Vanhoof and De Schrijver 1998, Fernandez, Roy et al. 2000). 
Several proposals have been suggested for the underlying mechanism of the 
cholesterol lowering effect, including: inhibition of 3-hydroxy 3-methylglutaryl CoA 
reductase, the rate limiting enzyme of cholesterol synthesis, or propionate 
enhancement of bile acid excretion by binding to starch granules and cholesterol 7α 
hydroxylase activity (Chezem, Furumoto et al. 1997, Arora, Sharma et al. 2011). The 
effects of RS on triglyceride levels are thought to be due to the increased production 
of fatty acids in the cecum. The absorption of the fatty acids reduces the activity of 
regulatory enzymes of fatty acid synthesis (Morand, Levat et al. 1994). 
Bronkowska et al (2013) studied the effect of RS4 in high fat diets. Four diets 
were tested, soybean oil without resistant starch, soybean oil with RS, lard with 
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cholesterol added, and lard with cholesterol and RS added.  Serum levels of total 
cholesterol were significantly lower in both diets supplemented with RS4. Levels of 
triglycerides were reduced similarly. Liver analysis showed that total cholesterol 
was reduced for both RS4 diets, and both RS4 diets showed higher HDL levels 
(Bronkowska, Orzel et al. 2013). Lopez et al (2001) determined that rats fed with RS 
had lower cholesterol in stool than control groups, as well as enhanced bile acid and 
cholesterol excretion. This could show that resistant starch may promote the 
conversion of cholesterol to bile acids for excretion (Lopez, Levrat-Verny et al. 
2000). Fernandez et al found lowered triglyceride and LDL cholesterol levels in 
guinea pigs fed with a diet supplemented with RS(Fernandez, Roy et al. 2000). 
Behall et al (1989) performed a study to determine the effects of amylose content on 
triglyceride, cholesterol levels, and other markers. Diets higher in amylose resulted 
in significantly lower total cholesterol and triglycerides. RS, which is higher in 
amylose than amylopectin, should show a similar effect (Behall, Scholfield et al. 
1989). Table 3 shows a summary of studies in which RS affected lipid metabolism.  
 Through fermentation in the large intestine, RS produces of short chain fatty 
acids. Propionate, a primary SCFA produced via fermentation of RS, is thought to 
attenuate cholesterol synthesis in the liver, while increasing HDL production (Soral-
Smietana and Wronkowska 2004). SCFA absorption is proposed to reduce the 
activity of fatty acid synthesis, which can decrease the production of triglycerides 
(Morand, Levat et al. 1994). The aforementioned studies performed upon rats 
showed a significant decrease in plasma total cholesterol levels with RS 
supplemented diets. Chezem et al (1997), however, observed a difference in total 
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cholesterol levels between different types of resistant starches, RS3 and RS4. 
Higgins et al (2004) found no significant effect of RS2 on blood triglycerides at doses 
of 10.7% RS or below. Further research should be considered to examine the effects 
of the different subcategories of RS on cholesterol levels. An analysis to determine 
the minimum amount of RS that needs to be consumed for a significant response 
should also be measured. Differing gut microflora profiles provide another 
possibility to the differences observed in the comparison of the studies. These 
studies do establish that long term dietary intake of resistant starches can maintain 
low serum lipids, which can be beneficial to cardiovascular and overall health.  
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Table 3. Resistant starch studies on lipid metabolism. 
Author(s) Subjects Model Design Parameters Measured Results 
Behall, Scholfield et al. 
(1989) 
 
 
Human subjects: 12 
males 
Cross over study. 
Subjects were 
subjected to either 
70% amylose or 70% 
amylopectin in starch 
diet, in which starch 
contributed to 34% of 
caloric intake, for 5 
weeks. Fasting blood 
was drawn each week, 
and a glucose tolerance 
test was administered 
after four weeks of diet 
consumption. 
Fasting blood was 
analyzed for glucose, 
insulin, triglycerides, 
cholesterol (total and 
HDL), urea nitrogen, 
and uric acid. 
Postprandial plasma 
was analyzed for 
glucose, insulin, and 
glucagon.  
- Mean fasting 
triglyceride and 
cholesterol levels were 
significantly lowered in 
during the period in 
which the men ate the 
70% amylose diet.  
Higgins, Higbee et al. 
(2004) 
Human subjects: 7 
male, 5 female 
Subjects received four 
meals differing in RS2 
content, 0%, 2.7%, 
5.4%, or 10.7% of total  
Blood samples were 
taken at 0, 30, 60, 90, 
120, 180, 240, 300, and 
360 minutes after the  
- Resistant starch had 
no significant effect on 
triacylglycerol levels, at 
any dose.  
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Table 3. Resistant starch studies on lipid metabolism (continued) 
Brites, Trigo et al. 
(2011) 
Rats: 36 male Wistar  Rats were fed breads 
consisting of 20% RS + 
wheat flour, wheat 
flour, 20%RS + maize 
flour, or maize flour for 
21 days. 
After a twelve hour 
fast, animals were 
euthanized and blood 
was collected for 
cholesterol and 
triglyceride analysis. 
- The RS + wheat fed 
group and the RS + 
maize fed group 
displayed significant 
reductions in blood 
total cholesterol.   
Kim, Chung et al. 
(2003) 
Rats: Sprague-Dawley Rats were fed diets 
containing 53% 
cornstarch, 23% 
cornstarch + 30% RS 
from corn, or 23% 
cornstarch + 30% RS 
from rice for three 
weeks. 
Fasting plasma lipids 
were measured 
through cardiac 
puncture after 
euthanasia. Liver lipids 
were also extracted 
and determined. 
- Both types of RS 
significantly lowered 
plasma total lipid and 
cholesterol 
concentrations 
compared to the 
control.  
- Total liver cholesterol 
was lowered in RS 
from rice fed rats 
compared to the 
control. 
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Table 3. Resistant starch studies on lipid metabolism (continued) 
De Deckere, Kloots et 
al. (1993) 
Rats: Male Wistar Diets contained either 
a low or high amount 
of RS, with a control 
group fed guar gum. 
Effects of RS on total 
cholesterol and 
triglycerides were 
measured.  
- Rats fed with RS had 
lowered total 
cholesterol in a dose 
dependent manner. 
- Rats fed with RS had 
lowered triglycerides 
in a dose dependent 
manner. 
Lopez, Levrat-Verny et 
al. (2000) 
Rats: 64 male Sprague-
Dawley 
Rats were fed diets 
consisting of 20% RS in 
the form of raw potato 
starch or high amylose 
starch.  
Blood was collected via 
cardiac puncture and 
analyzed for lipids.  
- Rats that consumed 
resistant starches had 
lowered cholesterol 
absorption by 23%.  
- RS diets were also 
effective in lowering 
plasma cholesterol. 
Fernandez, Roy et al. 
(2000) 
Guinea pigs: Male 
Hartley 
Diets consisted of 14% 
cellulose, 10% RS, or 
1% cholestyramine for 
4 weeks.  
Plasma total 
cholesterol, HDL 
cholesterol, and 
triglycerides were 
- Guinea pigs fed the 
resistant starch diet 
had lower plasma 
cholesterol than  
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Table 3. Resistant starch studies on lipid metabolism (continued) 
   measured after 
euthanasia. 
control.  
- No effects were 
observed for plasma 
triglycerides.  
- RS fed diets had lower 
LDL cholesterol levels 
than the control. 
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Resistant Starch: Fermentation and Short Chain Fatty Acid Production 
Starches that reach the large intestine undergo bacterial fermentation. 
Diverse populations of bacteria found in the proximal colon are the primary 
organisms responsible for this starch fermentation. This fermentation in the gut 
yields end products such as hydrogen gas, carbon dioxide, methane and short chain 
fatty acids (Englyst, Kingman et al. 1996, Hijova and Chmelarova 2007). 
SCFAs consist of 1 to 6 carbons, and are the preferred respiratory fuel of 
colonocytes. The principal SCFAs are acetate, propionate, and butyrate. In humans, 
acetate is present in the highest concentration, followed by propionate, then 
butyrate.  More recent studies have introduced roles of SCFAs such as advantageous 
to ion transport, modulators of intracellular pH, cell proliferation and differentiation 
regulators, and regulators of gene expression (Cook and Sellin 1998). 
Although all SCFAs can be used as fuel, butyrate is the favored respiratory 
fuel by colonocytes. Butyrate is converted to ketone bodies, which can be used as 
energy throughout the body (Scheppach 1994, Nugent 2005, Hijova and Chmelarova 
2007). This respiratory energy produced can be used for microbial growth and 
maintenance, or for production end products that can be absorbed through the 
intestinal wall and circulated throughout the body (Topping and Clifton 2001). 
Fermentation of starch, therefore, can signify salvage of energy of indigestible food 
(Bullock and Norton 1999). 
100-200 mM of SCFAs are produced daily, and are mostly absorbed by the 
colon (Cook and Sellin 1998). SCFAs are more rapidly absorbed in the colon when 
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the luminal pH is low, or when the levels of SCFAs are amplified. In an acidic 
environment, some intestinal bacterial pathogens are inhibited, which concludes 
that a lower pH would be beneficial for gut disease. SCFAs stimulate the absorption 
of water and sodium in the large intestine, which can in turn mitigate diarrhea 
(Soral-Smietana and Wronkowska 2004). The concentration of SCFAs decreases as 
following the lower digestive tract, found in the highest concentrations in the cecum 
and lowest in the distal colon (Cook and Sellin 1998). The site of resistant starch 
fermentation has been shown to potentially push more distally. As the distal colon is 
where most tumors arise, a low pH could be a major benefit to the protection and 
prevention against colon cancer by controlling cell growth, inhibiting bacterial 
pathogens, and controlling absorption. (Fuentes-Zaragoza, Sanchez-Zapata et al. 
2011). 
The liver utilizes acetate by converting it to acetyl-CoA, a precursor to the 
lipogenesis of long chain fatty acids and a stimulator of gluconeogenesis. Propionate 
is also metabolized in the liver, where it increases gluconeogenesis. Propionate has 
furthermore been found to attenuate cholesterol synthesis in the liver, as well as 
increase high-density lipoprotein production (Soral-Smietana and Wronkowska 
2004). 
Butyrate is metabolized in preference to glucose and glutamine by 
colonocytes as an energy-producing pathway in the form of ATP (Cook and Sellin 
1998, Henningsson, Bjorck et al. 2001, Soral-Smietana and Wronkowska 2004, 
Hijova and Chmelarova 2007). The metabolism of butyrate stimulates cell migration 
and proliferation, making it an important substrate in the colonic mucosa in its 
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prevention of colon disease (Soral-Smietana and Wronkowska 2004). Butyrate has 
been shown by Clarke et al (2012) to induce higher rates of apoptosis in rats 
exposed to genotoxic agents.  Apoptosis is an important process in the protection of 
damaged cells prone to malignancy (Clarke, Young et al. 2012). This result 
illustrates that butyrate possibly plays a role in the protection against colon cancer 
and disease.  
Kleessen et al (2014) found that RS2 caused higher acetate and propionate 
concentrations than an RS1 diet and RS-free diet. Butyrate concentrations were 
higher in both the RS1 and RS2 diets than in the RS-free diet. The butyrate was of 
equal concentration for both RS diets (Kleessen, Stoof et al. 1997). Ferguson et al 
(2000) treated rats with different preparations of RS2 starches, which resulted in an 
increase in all SCFAs. It was concluded that some RS2 starches had a more 
significant increase in butyrate concentrations, which would promote those 
starches as more beneficial to gut health when regarding cancer.  Butyrate is 
beneficial for colon cancer, as it has been found to reverse neoplastic changes 
(Ferguson, Tasman-Jones et al. 2000, Nugent 2005). Bullock et al (1999) found that 
addition of RS3 to the diet increased SCFAs proportional to dose (Bullock and 
Norton 1999). Langkilde et all (2002) performed a 24 hour in vitro study of raw 
green banana flour, which resulted in a increase of acetate and butyrate (Langkilde, 
Champ et al. 2002). These studies potentially show the potential benefit of RS on 
SCFA production, which would lead to improved gut health. Table 4 shows a 
summary of findings for RS effects on short chain fatty acids, particularly acetate, 
butyrate, and propionate. 
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Through fermentation in the large intestine, RS can produce SCFAs, including 
acetate, propionate, and butyrate. SCFAs are known to benefit gut health through a 
variety of mechanism, such as modulation of intracellular pH, ion transport, and 
gene expresion regulation (Cook and Sellin 1998). The following rat studies resulted 
in differing conclusions. Bullock et al (1999) observed a significant increase in SCFA 
production with increasing RS3 concentration, while Kim et al (2003) did not 
observe any significant differences. The reasons for the differing responses can be 
attributed to differing microflora profiles, or even type of RS. Investigation of the 
effects of different types of gut microflora and differing RS types should be 
considered to determine the specific effects of the parameters on SCFA production. 
These studies suggest that in humans, short chain fatty acid production, particularly 
acetate and butyrate, is increased when RS is consumed. Phillips et all (1995) found 
that SCFA concentration, mainly acetate and butyrate, increased in a dose 
dependent manner. However, only two doses of RS were tested. Further studies 
investigating the production of SCFA with different doses of RS should be 
considered, to determine a which doses can elicit a significant response.  
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Table 4. Studies of RS and fecal short-chain fatty acids.  
Author(s) Subjects Model Design Parameters Measured Results 
Langkilde, Champ et al. 
(2002) 
Human subjects: 10 
ileostomy subjects 
Subjects were given a 
diet with 30g RS2 (raw 
green banana flour) or 
a cooked banana flour.  
Ileostomy bags were 
changed every 2 hours, 
and contents were 
frozen for future 
analysis of SCFA.  
- Acetate and butyrate 
concentrations were 
significantly higher in 
the RS2 diets than the 
control and cooked 
banana diets. 
Phillips, Muir et al. 
(1995) 
Human subjects: 5 
male, 6 female 
Subjects consumed 
differing diets 
consisting of different 
amounts of RS 
(5.0g/day or 39.0 
g/day) for 3 weeks.  
Stool was collected the 
third week of the 
study.  
- Fecal concentration of 
acetate and butyrate 
were increased in a 
dose dependent 
manner. 
Kim, Chung et al. 
(2003) 
Rats: Sprague-Dawley Rats were fed diets 
containing 53% 
cornstarch, 23% 
cornstarch + 30% RS 
from corn, or 23% 
cornstarch + 30% RS  
At euthanasia, cecum 
contents were 
collected and 
immediately frozen. 
Contents were then 
analyzed for SCFAs.  
- No significant 
difference was 
observed in SCFA 
concentration for all 
groups.  
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Table 4. Studies of RS and fecal short-chain fatty acids (continued) 
  from rice for three 
weeks. 
  
Bullock and Norton 
(1999) 
Rats: 42 male Wistar  Rats were fed seven 
different diets, ranging 
from 0% RS3 to 200% 
RS3.  
Stool was collected 
from days 6 to 8, and 
gut contents were 
collected at euthanasia. 
- Total SCFA 
production increased 
with increasing RS3 
concentration. 
Kleessen, Stoof et al. 
(1997) 
Rats: 30 male Wistar  Rats were fed RDS, 
16.7% RS2 + waxy 
maize, or 66.75 RS2 + 
waxy maize for 5 
months. 
Fecal samples were 
collected eight days, 1 
month, 3 months, and 5 
months after the start 
of the experiment.  
- RS2 showed higher 
amounts of SCFAs, 
particularly acetate 
and propionate. 
Nofrarias, Martinez-
Puig et al. (2007) 
Pigs: 16 pigs Pigs were fed for 14 
weeks on a diet 
consisting of  raw 
potato starch (RS2) or 
cornstarch.  
At euthanasia, 
proximal colon 
contents were 
collected and analyzed 
for SCFAs.  
- Total SCFAs were not 
significantly different 
between treatments.  
- Acetate was larger in 
proximal colon for CS 
pigs than RPS pigs.  
- Butyrate was larger in 
RPS pigs than CS pigs. 
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Resistant Starch: Food Intake, Weight Maintenance, and Satiety 
The increasing presence of obesity in North America is convincing the 
country to develop strategies to reduce body weight and food intake to combat the 
issue. The effect of RS on lowering food intake may support the possibility of an 
increased satiety. This reduction of food intake directly impacts body weight, which 
could prove to be beneficial in weight loss and management (Freeland, Anderson et 
al. 2009).  Some research has proposed that high fiber foods, like RS, may increase 
gut hormone alterations, such as glucagon-like peptide 1 (GLP-1). GLP-1 is known to 
have physiological functions including increasing insulin secretion and decreasing 
glucagon secretion (Willis, Eldridge et al. 2009). Glucose level has been proposed to 
correlate with satiety. A low glucose response would signify lower food intake, 
which would show a greater satiety level.  
Measurement of satiety in animals is difficult, if not impossible, so 
determining satiety is left to studies on humans. Freeland et al (2009) studied the 
effects of fiber in a breakfast meal to healthy adult males. Males were fed a preload 
of low fiber cereal, high fiber cereal, low fiber cereal with glucose and high fiber 
cereal with glucose. They were then monitored for food intake for the remainder of 
the day. Energy intake was lowered in the glucose supplemented meals and the high 
fiber cereal preload. Satiety was greater in high fiber diets compared to the low fiber 
diets (Freeland, Anderson et al. 2009). Willis et al (2009) found that of the different 
dietary fibers, RS showed a significantly greater satisfaction and fullness up to 120 
minutes. These studies contribute to the concept of RS playing a key role in food 
intake and satiety, which could eventually lead to weight loss and control (Willis, 
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Eldridge et al. 2009). Nilsson et al (2007) found that after an evening meal of RS, 
subjects were more satisfied with a breakfast meal the following morning than the 
control (Nilsson, Ostman et al. 2007). 
Brites et al (2011) showed that RS supplemented wheat diets yielded 
significant reductions in food intake, but did not significantly alter body weight in 
rats (Brites, Trigo et al. 2011). Aziz et al (2009) determined that obese rats fed RS 
had a significantly reduced energy intake (Aziz, Kenney et al. 2009). Bodinham et al 
(2010) completed a short-term study of resistant starch ingestion on food intake. 
Subjects consumed 48g of RS in test meals, and were required to keep a food log for 
24 hours. Subjects that received the RS test meals consumed less food for the 24-
hour period than the controls (Bodinham, Frost et al. 2010).   
RS primarily causes satiety due to its indigestibility. Satiation is assumed to 
influence food intake, but the proportion of satiation and food intake is difficult to 
determine. However, if weight loss is the endpoint, a lowered food intake is a key, 
and additional studies are needed to examine the effects of RS on weight loss. It 
would be necessary to determine if the weight loss thought to be associated with RS 
is due to a reduced food intake, which would be due to a higher satiety, or another 
mechanism involving satiety signaling and hormones.  
 
Resistant Starch: Adverse Effects 
 The consumption of RS has been associated with belching, flatulence, 
laxation, gas emission, nausea, and stomach pain (Grabitske and Slavin 2009). 
Heijnen et al (1996) completed a single blind study in which 27 males and 30 
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females were provided RS2 or RS3 supplements, totaling 30g daily for 3 weeks 
along with their normal food consumption habits. The results concluded that a dose 
of more than 30g/day of RS caused flatulence, bloating, belching, stomachache, and 
mild laxative effects (Phillips, Muir et al. 1995, Heijnen, Van Amelsvoort et al. 1996). 
Heijnen et al (1998) also performed a study in which 24 healthy men ingested a 
daily RS2 or RS3 supplement (32g/day) for 4 weeks in addition to their normal diet. 
91% of subjects supplemented with RS3 and 82% of subjects supplemented with 
RS2 reported flatulence. Bloating was reported in 41% of RS3 supplemented 
subjects and 28% of RS2 supplemented subjects (Heijnen, Van Amelsvoort et al. 
1998). Phillips et al (1995) completed a study in which 11 volunteers (5 male, 6 
female) were subjected to a cross over study of high-RS diet (39g/day) or a low-RS 
diet (5g/day) for 3 weeks, where stool was collected and gastrointestinal symptoms 
were recorded. A significant level of flatulence was reported in participants fed a 
high-RS diet, concluding that at high doses, RS causes flatulence in humans (Phillips, 
Muir et al. 1995). 
 Gastrointestinal discomfort due to RS is not observed at lower doses, but 
some symptoms were observed at higher doses. These results conclude that at 
higher doses, such as 30g/day or higher, can cause gastrointestinal discomfort like 
flatulence and bloating. However, at these doses, additional gastrointestinal adverse 
effects were minimally reported. Additional research should be considered to 
determine which doses of RS can be consumed that do not cause gastrointestinal 
discomfort while still eliciting the positive effect on the aforementioned parameters.  
 
Resistant Starch: Mitigation of Diarrhea 
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Diarrhea is an excessive loss of fluid in the feces. The benefit of starch to 
diarrheal disease can be contributed to increased fluid absorption through greater 
SCFA production. SCFAs stimulate the uptake of water and cations in the proximal 
colon. Examples of cations that SCFAs promote include sodium, calcium, 
magnesium, and potassium. These cations are commonly associated with decreased 
fluid loss due to diarrhea. Lopez et al (2001) observed an increase in absorption of 
zinc, magnesium, and calcium in rats fed resistant starch (Lopez, Levrat-Verny et al. 
2000). Trinidad et al (1996) showed that calcium is absorbed in the colon, and the 
absorption is enhanced by increased SCFAs. It was also found that propionate 
stimulates calcium absorption at a higher level than acetate (Trinidad, Wolever et al. 
1996). 
RS improves stool consistency in diarrhea by isolating water from the liquid 
stool. The water holding capacity of RS allows for the absorption of the excess water 
characterized in diarrhea, ultimately increase fecal bulk (Bosaeus 2004). Cummings 
et al (1993) found that a significant increase in stool weight in subjects fed RS2 and 
RS3 (Cummings, Beatty et al. 1996).  Along with the mitigating effects of fecal bulk 
on diarrhea, an increase in fecal bulk is also associated with the decreased incidence 
of colon cancer (Fuentes-Zaragoza, Sanchez-Zapata et al. 2011). 
Minerals are absorbed by exchange with a hydrogen ion in the large 
intestine. SCFAs are protonated, and when they diffuse into colonocytes, they 
dissociate and release a proton.  The dissociation of hydrogen stimulates a Na-H 
exchange, resulting in mineral absorption (Cook and Sellin 1998). The transfer of 
the hydrogen ion into the lumen would decrease the pH in the colon (Trinidad, 
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Wolever et al. 1996). A pH lowered by 0.5 units has been associated with a reduced 
risk of colon cancer (Brites, Trigo et al. 2011). 
Lower pH in the colon promotes the fecal excretion of bile acids and neural 
sterols, because the lower pH lowers the solubility of secondary bile acids 
(Jacobasch, Schmiedl et al. 1999). Le Leu et al (2002) found that pH was lowered 
with a RS supplemented diet (Leu, Hu et al. 2002). Brites et al (2011) also found that 
diets supplemented with RS produced lower fecal pH than diets without RS, 
regardless of the type of starch mixed with the RS (Brites, Trigo et al. 2011). 
SCFAs in the large intestine also promote blood flow through the viscera, 
which allows for more nutrient absorption, again decreasing diarrhea (Trinidad, 
Wolever et al. 1996). Increased blood flow could also promote cell proliferation 
(Cook and Sellin 1998). 
SCFA has also been thought to limit the viability of cholera in the gut. It has 
been hypothesized that the bacteria adhere to the resistant starch granules, 
therefore removing the bacteria from the infection site. Topping et al (2003) found 
that total coliforms and E. coli lowered in the proximal colon after exposure to 
amylose starch (Topping, Fukushima et al. 2003). 
To summarize, RS is thought to reduce diarrhea through SCFA production 
and its high water holding capacity. The proposed method for the reduction in 
diarrhea is that of increased stool bulk though a healthier gut flora. Gut flora 
increase and become more diverse through the production of SCFAs, the primary 
fuel source for these bacteria. The results mentioned in table 5 conclude a variety of 
findings. Explanations for these differences can be contributed to differing gut 
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microflora profiles, different tolerances to the starches, or differing water holding 
capacity between the resistant starch subtypes. Analyses looking further into 
microflora composition would be a good subject to explore to determine the 
mechanisms of RS on influencing the microflora, or its direct effects on gut barrier 
function through SCFA production.  
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Table 5. Studies of RS effects on diarrhea.  
Author(s) Subjects Model Design Parameters Measured Results 
Nofrarias, Martinez-
Puig et al. (2007) 
 
Pigs: 16 pigs Pigs were fed for 14 
weeks on a diet 
consisting of raw 
potato starch (RS2) or 
cornstarch.  
At euthanasia, 
proximal colon 
contents were 
collected, weight, and 
measured for starch 
content. 
- Colon content was 
significantly heavier in 
resistant starch fed 
pigs than control. 
- Upon analysis of 
starch, more starch 
was found in the 
proximal colon of the 
RS2 fed pigs than 
control. 
Bhandari, Nyachoti et 
al. (2009) 
Pigs: 84 piglets Piglets were subjected 
7% RS or 14% RS to 
treat post-weaning 
diarrhea.  
Stool consistency was 
measured daily.  
- 7% RS treatment 
improved stool 
consistency, however, 
14% RS did not.  
Cummings, Beatty et al. 
(1996) 
Human subjects: 7 
male, 5 female 
Subjects consumed 
diets consisting of 17-
30g/day of RS for 15 
days. 
Stool was collected, 
weighed, and then 
freeze-dried to 
constant weight. 
- Stool weight/bulk 
was significantly 
increased in RS diets.  
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Table 5. Studies of RS effects on diarrhea (continued) 
Ramakrishna, 
Subramanian et al. 
(2008) 
Human subjects: 50 
males 
Oral rehydration 
therapy was admitted 
at 50g/L RS.  
Total diarrhea fecal 
weight was measured 
as well as duration of 
diarrhea. 
- High amylose maize 
starch reduced 
diarrhea duration by 
55%.  
Raghupathy, 
Ramakrishna et al. 
(2006) 
Human subjects: 183 
children 
Subjects were given 
oral rehydration with 
50 g/L RS or glucose.  
Stool consistency and 
weight were measured 
until the development 
of formed stool or until 
72 hours past therapy.  
- Formed stool was 
developed significantly 
faster in RS treated 
children.  
Rabbani, Teka et al. 
(2001) 
Human subjects: 62 
boys 
Subjects were given 
diets consisting of 
either 250 g/L green 
banana or 4 g/kg 
pectin, or a rice diet 
alone.  
Stool weight, 
frequency, and 
consistency were 
measured.  
- Subjects receiving 
pectin or banana 
recovered from 
diarrhea faster than 
control.  
- Subjects receiving RS 
treatment improved 
stool consistency 
significantly. 
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Resistant Starch: Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is a disease that is chronic and without a 
medical cure. IBD is most commonly present in developed western countries, 
including the United States. There are approximately 2.2-14.3 new cases of colitis 
per 100,000 people per year and 3.1-14.6 new cases of Crohn’s disease per 100,00 
people per year.  More developed countries, like the United States, have different 
lifestyles, diets, and environmental exposures that could be the underlying reason 
for the high incidence of IBD in these areas (Loftus 2004). 
The trademark symptom of IBD is uncontrollable inflammation of the 
intestinal mucosa. Inflammation can occur in any part of the digestive tract. 
Unfortunately, in IBD, inflammation is not down regulated, so patients are 
chronically inflamed. Dysfunctional immune host response, pathogen infection, or a 
defective mucosal barrier potentially causes the immunoregulatory defects of IBD 
(Hanauer 2006). 
Ulcerative colitis is a chronic disease in which there is ulceration of the 
colonic mucosa and submucosa. SCFA enemas are a type of treatment for ulcerative 
colitis in humans. It has been suggested that if resistant starch increased SCFA 
production, then it may be a useful treatment for inflammatory bowel diseases like 
colitis (Nugent 2005). Diversion colitis is an inflammatory disease characterized by 
changes in crypt abscesses, lymphoid hyperplasia, ulceration, edema, and other 
histological parameters (Cook and Sellin 1998). Symptoms of colitis include 
diarrhea, rectal bleeding, abdominal pain, constipation, loss of appetite, and weight 
loss.  
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IBD is associated with disruption of tight junctions in the epithelium of the 
gut, which can increase permeability of the lining. A normal lining protects against 
luminal microbes and antigens, and regulates activation of immune responses. In 
IBD, since the barrier is altered, bacterial products are able to cross the barrier and 
come in contact with immune cells. The immune cells will respond and cytokines 
will be produced, leading to the addition of inflammatory cells to the epithelium, 
creating inflammation (Hanauer 2006). 
IBD alters some specific inflammatory and immune regulators. The activity of 
Nuclear Factor kappa B, a transcription factor in inflammatory responses and 
macrophage apoptosis, is increased in IBD. Activation of NF-κB yields the 
production of cytokines, growth factors, and metabolites of reactive oxygen, which 
facilitate inflammation and can contribute to tissue damage (Hanauer 2006). 
RS has been reported to influence the production of pro-inflammatory 
cytokines and the expression of the receptors on T- and B-lymphocytes that trigger 
immune responses. This can be partially attributed to the favored SCFA, butyrate. 
Segain et al (2000) reported that butyrate can directly inhibit inflammatory 
responses through down regulation of NF-κB, which is commonly increased in cases 
of IBD (Segain, Raingeard de la Bletiere et al. 2000, Nugent 2005). 
Increased SCFA production also decreases luminal pH. One outcome of a 
lower pH in the lumen signifies a lower the activity of 7α-hydroxylase, the enzyme 
associated with the rate limiting step of bile acid synthesis. Another outcome of a 
lower pH in the lumen is the inhibition of the transformation of primary to 
secondary bile acids, particularly cholate into deoxycholate. Deoxycholate inhibits 
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proliferation in the rat colitis model (Jacobasch, Schmiedl et al. 1999). Fernandez et 
al (2000) however, did not find a significant lower 7α-hydroxylase activity in guinea 
pigs fed RS2 (Fernandez, Roy et al. 2000). 
Harig et al (1989) found that in patients with colitis subjected to SCFA 
edemas, endoscopic score improved significantly. After cessation of the treatment, 
the scores worsened. This study revealed a potential benefit of SCFAs to colon 
health, as the replacement of SCFAs improved inflammation (Harig, Soergel et al. 
1989). Breuer et al (1991) conducted a study with patients with distal colitis. 90% 
of the subjects improved histologically after twice daily SCFA irrigations for 6 weeks 
(Breuer, Buto et al. 1991). 
Oral rehydration therapy is a common treatment for diarrheal disease. 
Ramakrishna et al (2000) administered oral rehydration solutions containing 50 g 
resistant starch in adolescents and adults with cholera. Mean duration of diarrhea 
for patients was significantly lower with the resistant starch solution. This 
concludes that RS as a supplement in oral hydration therapy can help reduce fluid 
loss (Ramakrishna, Venkataraman et al. 2000). 
In the study of Jacobasch et al (1999) rats induced with colitis were fed RS2 
diets. Histological markers of inflammation and normalization were improved. 
Markers that improved included colonic cell proliferation, uptake of SCFA, and 
restoration of apoptosis (Jacobasch, Schmiedl et al. 1999, Nugent 2005). Moreau et 
al (2003) tested resistant starch on rats with dextran sodium sulfate induced colitis, 
and found improvements in histological observations (Moreau, Martin et al. 2003). 
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Typical treatments for inflammatory bowel disease and colitis include fecal 
bulking agents and fiber. This makes RS a prime choice for treatment of such a 
disease. The mechanism of RS on the improvement of gut barrier function and 
inflammation associated with IBD should be contemplated. This could provide a 
future dietary treatment for inflammatory bowel diseases, like colitis.  
 
Citrobacter rodentium  
Citrobacter rodentium (C. rodentium) is a murine attaching and effacing 
pathogen that is used in laboratory mice. It produces lesions indistinguisible from 
those of Escherichia coli (E. coli) (Higgins, Frankel et al. 1999). This pathogen 
attaches to enterocytes of host mice and efface the cell microvilli to produce 
diarrhea and inflammation (Guttman, Lin et al. 2009). 
C. rodentium has a similar virulence to E. coli, however, fecal shedding was 
several orders of magnitude higher in C. rodentium than in E. coli. The duration of C. 
rodentium shedding was three to four weeks. Unlike E. coli, C. rodentium has 
reproducibly infected mice and has caused colonic disease (Borenshtein, McBee et 
al. 2008). 
Clinical signs induced by C. rodentium include: dehydration, weight loss, coat 
ruffling, reluctance to move, diarrhea, and high mortality.  These symptoms are 
similar to the characteristics of IBD. IBD patients are also at a high risk of colorectal 
cancer, and C. rodentium can cause a similar risk due to the hyperplasia of the 
mucosal lining (Borenshtein, McBee et al. 2008). 
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Citrobacter rodentium: Hyperplasia 
C. rodentium causes epithelial hyperplasia in the distal colon. Hyperplasia is 
described as hyperproliferation of cells associated with NF-κB 
activstion(Borenshtein, Nambiar et al. 2007). As stated previously, activation of NF-
κB produces growth factors, reactive oxygen metabolites, and cytokines, all of which 
contribute to inflammation and tissue damage. NF-κB can be activated in the 
following way: due to proinflammatory cytokines lead to the activation of IKK, 
which phosphorylates NF-κB-bound IκBs, releasing NF-κB to bind cytokines, 
chemokines, immunorecetors and other target genes (Borenshtein, Nambiar et al. 
2007, Borenshtein, McBee et al. 2008). Increases in NF-κB activity due to C. 
rodentium have been seen in mice as early as 3 days postinoculation and increased 
through 12 days postinoculation. Wang et al (2006) found that on day 12 
postinoculation, gland hyperplasia was at its maximum (Wang, Xiang et al. 2006). 
 
Citrobacter rodentium: Development of Diarrheal Illness and IBD 
Diarrheal illness leads to dehydration, which can be life threatening. 
Potential causes of diarrhea with C. rodentium include disruption of tight junctions 
resulting in impairment of intestinal barrier function, alterations in active transport, 
alterations in enteroendocrine serotonin signaling, and mucosal serotonin signaling. 
Gap junctions are key structures for the normal function of tissues. They provide 
intercellular channels for molecule movement. C. rodentium can cause changes in 
localization of aquaporins 2 and 3 (AQP2 and AQP3). AQP2 and AQP3 are water 
channels involved in water transport in intestinal epithelial cells. They conduct 
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water molecules through the cell and prevent the transport of unwanted ions. The 
changes due to C. rodentium can lead to water and electrolyte retention, in which the 
consequence is diarrhea (Borenshtein, McBee et al. 2008). 
E. coli infection presents a significant health risk, especially in developing 
countries. Strains of E.coli can lead to diarrhea, dehydration, and death in some 
situations. A significant disease that can arise from E. coli is hemorrhagic colitis, 
which can be fatal. Causation of diarrheal illness in humans due to E. coli includes 
changes in the epithelium to lessen absorption, tight junction integrity loss, and 
permeability changes, all which lead to tissue damage. As stated above, C. rodentium 
has similar effects, allowing it to be a useful model for acute diarrheal disease and 
other gastrointestinal diseases like IBD. Mechanisms of C. rodentium infection are 
homologous to those with E. coli in humans, including the large number of bacterial 
attachment to the epithelial cell surface, thinning of the brush border, and epithelial 
extension beneath the bacteria (Luperchio, Newman et al. 2000, Lebeis, Bommarius 
et al. 2007). 
 IBDs, like colitis, can be mimicked by pathogens such as C. rodentium. The 
mechanisms behind this are thought to be disruption of tight junctions, alterations 
in active transport, and alterations in serotonin signaling in the mucosal lining of the 
gut.  
 
Citrobacter rodentium: Host Defense 
The C. rodentium infection is self-limiting, and it takes approximately 7 days 
for the bacteria to colonize. The infection takes about three to four weeks for 
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clearance. Most adult mice have been shown to have a lower morality rate with C. 
rodentium than younger mice (Luperchio, Newman et al. 2000). Fortunately, mice 
that recover from the C. rodentium infection have been shown to be resistant to the 
infection when further challenged  (MacDonald, Frankel et al. 2003). 
B- and T- cells are needed to survive infection with C. rodentium in mice. T-
cell help results in B-cell maturation and IgG production. IgG has been shown to be 
protective against C. rodentium infection, as it can be transported across the 
epithelial barrier of the gut (Borenshtein, McBee et al. 2008). 
Studies that involve infection via C. rodentium are shorter-term studies, due 
to the self-limiting property of the pathogen. Effects of the pathogen are also not 
likely to be shown until 7 days postinoculation. The drawback to this type of model 
is the limit of length that a study can be performed due to the time to onset and 
quick clearing of C. rodentium. 
 
Citrobacter rodentium: Histological Changes 
Generally accepted histological changes found in mice infected with C. 
rodentium include goblet cell loss, epithelial cell hyperplasia, and crypt elongation. 
These effects are commonly seen in inflammation (Luperchio, Newman et al. 2000). 
Borenshtein et al (2007) found that FVB mice developed substantial inflammation, 
edemas, and ulceration in the colon after inoculation of C. rodentium. The changes 
were most severe in the mid to distal colon and did not involve the cecum. Other 
changes seen in the C. rodentium infected mice included loss of goblet cell 
differentiation and dysplasia (Borenshtein, Nambiar et al. 2007). Hyperplasia is 
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associated with changes like crypt hyperplasia, crypt dilation, epithelial cell 
proliferation, mucosal height elevation, and an uneven apical enterocyte surface  
(Higgins, Frankel et al. 1999). 
Higgins et al (1999) studied the histopathological results of the C. rod 
infection. By day 6, 60% of the mice experienced thickening of the distal colon. All 
mice experienced thickening by day 12. Epithelial cell hyperplasia was increased 
two to fourfold in the wild-type bacteria infected mice (Higgins, Frankel et al. 1999). 
To summarize, common histological changes to expect from the C. rodentium model 
are goblet cell loss, epithelial cell hyperplasia, crypt elongation, edema, and mucosal 
height elevation.  
 
Study Overview 
Purpose: The purpose of this study was to examine the effects of a chemically 
modified resistant starch, RS4, on diarrhea and inflammation induced by C. 
rodentium. We hypothesized that a diet supplemented with RS4, contributing to 
25% resistance of the total starch in the diet (55% starch diet), would significantly 
improve stool consistency and provide protection against the inflammation 
associated with the C. rodentium pathogen, including inflammation score, mucosal 
height, ulceration, goblet cell loss, edema, and hyperplasia.  
 
Design: 36 mice (18 male, and 18 female) were randomly assigned four treatment 
groups: uninfected mice fed the control starch diet, uninfected mice fed the RS4 
supplemented diet, C. rodentium infected mice fed the control starch diet, and C. 
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rodentium infected mice fed the RS4 supplemented diet. After inoculation with C. 
rodentium, mice were be subjected to the diets for two weeks, and daily food intake, 
body weight, and stool consistency were measured. At the completion of the two 
weeks, mice were euthanized and blood was collected via cardiac puncture for 
serum glucose, insulin, and lipid analysis. Colon and cecum contents were collected 
and analyzed for pH, stool fat, and water content; and the tissues were sent for 
histopathology scoring.  
 
Expected results: C. rodentium infected mice fed the RS4 supplemented diet were 
expected to show a significant increase in stool consistency compared to the 
infected mice the fed the control starch diet. The infected mice fed the RS4 diet were 
also expected to have a less severe inflammatory response due to the C. rodentium 
compared to the infected mice fed the control diet, which would be seen in the 
histopathology scores. Body weight loss and decreased food intake due to the C. 
rodentium pathogen was expected to be less severe in mice fed the RS4 
supplemented diet, due to its expected protection against inflammation and 
diarrhea.  
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CHAPTER III 
TYPE 4 RESISTANT STARCH DIMINISHES CITROBACTER RODENTIUM 
INDUCED DIARRHEA IN C3H MICE 
Kirsten Larson, Tae Yong Kim, Jesse Hostetter,  
and Suzanne Hendrich 
 
ABSTRACT 
Colitis is a chronic disease without medical cure, characterized by 
uncontrollable inflammation of the colonic mucosa and diarrhea. Resistant starch is 
a type of dietary fiber that is thought to improve upon stool consistency and 
inflammation via production of short chain fatty acids and absorption of water by 
the starch. Citrobacter rodentium, an A/E pathogen, mimics the inflammation and 
diarrhea associated with colitis. We hypothesized that a RS4 supplemented diet 
would reduce the severity of diarrhea and inflammation in the C. rodentium mouse 
model. C3H mice were inoculated with 5x108 CFUs of C. rodentium (12 male, 12 
female) or LB broth (6 male, 6 female). Two diets were tested, a RS4 supplemented 
diet contributing 25% resistance of total starch (12 C. rodentium infected, 6 
uninfected) and a control cornstarch diet (12 C. rodentium infected, 6 uninfected). 
Stool consistency, body weight, and food intake were measured daily for 14 days. At 
euthanasia, colon and cecum contents were removed for analysis of pH, water 
content, and fat content; and the tissues were sent for histopathology scoring. C. 
rodentium infected mice fed the control diet exhibited significant weight loss 
compared to the C. rodentium infected mice fed the RS4 diet. Infected mice fed the 
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control diet displayed a significantly lowered food intake compared to the 
uninfected mice on the control diet. Infected mice fed the RS4 diet did not display a 
significant decrease in food intake compared to the uninfected mice fed the RS4 diet. 
A significant increase in stool consistency was observed for infected mice fed the 
RS4 diet compared to the infected mice fed the control diet. When the significance 
level was increased to 0.10, infected mice fed the RS4 diet showed significant 
improvement on ulceration/epithelial injury, gland hyperplasia, and goblet cell loss.  
The results indicate a RS4 supplemented diet can reduce the severity of diarrhea 
caused by the C. rodentium mouse model, as well as provide a partial protection on 
the associated inflammation. Additional research should be considered to 
investigate mechanisms of RS4 on inflammation and gut barrier function. 
 
INTRODUCTION 
Inflammatory bowel disease (IBD), including colitis, is a chronic disease 
without cure. Its trademark symptoms are diarrhea and uncontrollable 
inflammation of the intestinal mucosa. IBD is most commonly present in developed 
western countries, including the United States. The underlying reason behind the 
high incidence of IBD in these areas has been proposed to be due to differing 
lifestyles, diets, and environmental exposures (Loftus 2004).  
The trademark symptoms of IBD, or colitis, involve diarrhea and 
uncontrollable inflammation of the intestinal mucosa. Inflammation can occur in any 
part of the digestive tract and is not down regulated, causing the inflammation to be 
chronic. Dysfunctional immune host response, pathogen infection, or a defective 
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mucosal barrier potentially causes the immunoregulatory defects of IBD and colitis 
(Hanauer 2006). 
Resistant starch (RS) can be defined as any starch that resists digestion in the 
small intestine, and passes to the large intestine where it is subjected to 
fermentation (Englyst and Hudson 1996, Nugent 2005). RS is thought to be 
beneficial to gut health, through its fermentation in the large intestine to create 
short chain fatty acids. The production of short chain fatty acids is thought to 
improve gut barrier function, which can be beneficial to diarrheal and colonic 
diseases. In conjunction with the production of short chain fatty acids (SCFAs), RS 
has a high water holding capacity, thought to increase stool bulk and consistency, 
lessening the degree of water in stool. It has been suggested that if RS increases 
SCFA production, then it may be a useful treatment for inflammatory bowel diseases 
like colitis (Nugent 2005). 
Citrobacter rodentium (C. rodentium) is a murine attaching and effacing 
pathogen that is used in laboratory mice. It produces lesions indistinguisible from 
those of Escherichia coli (Higgins, Frankel et al. 1999). This pathogen attaches to 
enterocytes of host mice and efface the cell microvilli to produce diarrhea and 
inflammation (Guttman, Lin et al. 2009). Clinical signs induced by C. rodentium 
include: dehydration, weight loss, coat ruffling, reluctance to move, diarrhea, and 
high mortality.  
Potential causes of diarrhea with C. rodentium include disruption of tight 
junctions resulting in impairment of intestinal barrier function, alterations in active 
transport, and alterations in enteroendocrine serotonin signaling (Borenshtein, 
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McBee et al. 2008). Generally accepted histological changes found in mice infected 
with C. rodentium include goblet cell loss, epithelial cell hyperplasia, and crypt 
elongation. These effects are commonly seen in inflammation (Luperchio, Newman 
et al. 2000). Borenshtein et al (2007) found that FVB mice developed substantial 
inflammation, edemas, and ulceration in the colon after inoculation of C. rodentium. 
The changes were most severe in the mid to distal colon and did not involve the 
cecum (Borenshtein, Nambiar et al. 2007). The similarity of the gastrointestinal 
effects of C. rodentium and IBD allow for the C. rodentium mouse model to be 
suitable for examining potential treatments for mitigation of the chronic disease.  
The purpose of this study was to examine the effects of a type-4 resistant 
starch (RS4) on diarrhea and inflammation in C3H mice triggered by C. rodentium, 
an A/E pathogen that causes inflammation and diarrhea similar to that of colitis. It 
was hypothesized that a diet supplemented with RS4 would primarily increase stool 
consistency in mice inoculated with C. rodentium. The RS4 diet treatment would also 
cause mice to experience a less severe inflammatory response due to the C. 
rodentium, which include goblet cell loss, mucosal height elevation, hyperplasia, 
edemas, and ulceration.  
 
MATERIALS AND METHODS 
Animals and Housing 
Eight-week-old C3H mice, 18 male mice and 18 female mice, were purchased 
from Harlan Bioproducts (Indianapolis, IN).  Animals were housed individually in 
micro-isolator cages. Each cage contained a raised wire floor, for determination of 
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stool consistency and stool weight. Mice were maintained on a 12-hour light/dark 
cycle in a temperature-controlled room. Temperature was maintained at 70°F. 
Water and food were provided ad libitum throughout the experiment. The animal 
studies were performed in compliance with the guidelines of the Iowa State 
University Institutional Animal Care and Use Committee (IACUC). 
 
Diets 
Two starches were evaluated in this study: a control starch, CS (Corn Starch 
CA 160170; Harlan Teklad, Madison, WI), and type-4 resistant starch, RS4 (RS-
FiberGel60, DAESANG Corp., Seoul, Korea). Each starch was analyzed for resistant 
starch content, or insoluble fiber content, according to the AOAC method 991.43 for 
total, soluble, and insoluble dietary fiber. The RS4 was found to contain 69.3% 
resistant starch, and the control starch contributed 1.2% resistance.  
Diets were a modification of the AIN-93G diet, in which total starch 
contributed 55% by weight of the total diet (Reeves 1997).  The resistant starch diet 
was modified to reduce the resistance to approximately 25% insoluble fiber. This 
was accomplished by mixing the resistant starch with the control starch. Table 1 
summarizes the resistant starch content for the starches and the mixture of the RS4 
and control starch added to the diet. Diets were prepared according to Zhou et al., 
where starches were added by dry weight (Zhao, Hasjim et al. 2011). Diets were 
prepared daily, and were fed to the mice after a 24-hour drying period. Table 2 
details the components of each diet, modified from the AIN-93G diet. Table 3 
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includes details for the caloric value of diet constituents, as well as grams of 
ingredient per kg diet.   
 
Table 1. RS Content of Starches and RS Diet Mixture, According to AOAC 991.43 
Starch Type Resistant Starch Content (%) 
Control Starch (CS) 1.2 ± 0.9 
Resistant Starch (RS4) 69.3 ± 16 
Diet Starch Mixture- RS4 + CS  25 
 
Table 2. Diet Ingredients for the Control Starch Diet and the RS with Control Starch 
Diet.  
Diet Ingredient Control Starch Diet RS4 Starch Diet 
Control Starch (CS) 55% ~36.7% 
Resistant Starch (RS4) - ~18.3% 
Casein 20% 20% 
Dextrose 15% 15% 
Mineral Mix (AIN-93) 3.50% 3.50% 
Vitamin Mix (AIN-93) 1% 1% 
Methionine 0.30% 0.30% 
Choline 0.20% 0.20% 
Corn Oil 5% 5% 
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Table 3. Caloric Value and g/kg in Control Diet and Resistant Starch Diet.  
Diet Ingredient 
CS Diet 
(g/kg diet) 
CS Calorie Content 
(kcal/g) 
RS4 Diet 
(g/kg diet) 
RS4 Diet Calorie 
Content (kcal/g) 
Control Starch 
(CS) 
550  CS 2.2 
~183 RS4  0.7 RS4  
Resistant Starch 
(RS4) 
~367 CS 1.5 CS 
Casein 200 0.8 200 0.8 
Dextrose 150 0.6 150 0.6 
Mineral Mix 
(AIN-93) 
3.5 - 35 - 
Vitamin Mix 
(AIN-93) 
10 - 10 - 
Methionine 3 - 3 - 
Choline 2 - 2 - 
Corn Oil 50 0.45 50 0.45 
 
Citrobacter rodentium culture 
The initial culture suspension of C. rodentium (ATCC, DBS100, 51459; 
Manassas, VA) was diluted to a 105 dilution and incubated overnight at 37°C. Serial 
dilutions were made at factors of 106, 107, 108, and 109. LB agar plates were 
prepared in water, and 100uL of the dilutions of C. rodentium samples were 
streaked onto the plate. After overnight culture at 37°C, colonies were counted to 
calculate the CFUs in the stock solution. Based upon the counts, the stock solution 
contained 1.7x1013 CFU/mL stock solution. To make a solution of 5x108 CFUs per 
100 uL, the stock solution was diluted 104 with LB broth, and incubated overnight at 
37°C. This final solution was used to inoculate the mice with 100 uL of solution by 
oral gavage. 
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Procedures 
Mice were randomly assigned to the two test diets based upon weight, for a 
mean weight of 20.38 ± 1.72 grams and 28.6 ± 1.75 grams for females and males, 
respectively, in each diet group. Mice were allowed to acclimate for one week on a 
modified AIN-93G diet before being fed the test diets (Harlan Teklad, Madison, WI). 
Body weight was measured at the start and once at the end of the week acclimation 
period.    
Mice were also assigned to C. rodentium treatment groups, infected or non-
infected. Those assigned to the C. rodentium treated group were inoculated by 
gavage with 100uL of LB Broth containing 4-5x108 CFUs of C. Rodentium 
(Borenshtein, Nambiar et al. 2007). Mice that were placed in the non-infected group 
were gavaged with 100uL of LB Broth with no C. Rodentium in the suspension. 
Body weight, food intake, water intake, and stool consistency were measured 
daily for 14 days after C. rodentium infection. Two days before euthanasia, stool was 
weighed along with measurement of stool consistency.  
Mice were fasted for 12 hours prior to euthanasia. Fresh stool was collected 
immediately before euthanasia to be used for determination of pH and fat content. 
At euthanasia, blood was collected by cardiac puncture, approximately 0.5 mL per 
mouse. The blood was then allowed to sit for 30 minutes to 1 hour, centrifuged at 
3500 rpm for 15 minutes in an Eppendorf 5418 Centrifuge (Eppendorf; Hamburg, 
Germany), and serum collected for analysis of glucose, insulin, and lipids. Serum was 
stored at -80° C before analysis. The colon and cecum of each mouse were removed, 
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and the contents collected and dried to determine water content. The tissues 
collected were stored in 10% formalin and analyzed for gut histopathology. 
 
Blood Analysis 
Fasting serum glucose was measured using YSI 2700 Select Biochemistry 
Analyzer (YSI Incorporated; Yellow Springs, OH). Fasting serum insulin was 
determined with Mercodia Ultrasensitive Insulin ELISA kit (Mercodia AB; Uppsala, 
Sweden). Serum lipids measured included: high-density-lipoprotein cholesterol, 
low-density-lipoprotein cholesterol, and triglycerides. Lipids were measured using 
Abnova HDL and LDL/VLDL standard kits and Abnova Triglyceride Quantification 
kit (Abnova; Taipei, Taiwan).  
 
Stool Consistency, Fat, and pH 
Stool consistency was graded on a 5-point scale, according to Hall et al (Hall, 
Melendez et al. 2013). A grade of 1 was assigned to feces that were not solid and 
were comprised of more than 75% liquid. A grade of 2 was given to feces that were 
soft and mounded, and that were consisting of 50% liquid. A grade of 3 was assigned 
to feces that had some cylindrical shape and more than 75% solid. A grade of 4 was 
assigned to feces that were more than 75% cylindrical and if more than 50% of the 
feces were firm. A grade of 5 was assigned to feces if the feces were cylindrical and 
more than 80% firm.  
Stool samples were collected prior to euthanasia, and samples were 
measured out and mixed vigorously with water, 3 mL per 100 mg of colon content. 
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(Norman J. Temple and El-Khatib 1987)  Stool pH was measured using a glass 
electrode and Corning pH/ion analyzer 350 (Corning). 
Stool fat was measured using a modified method from a method determined 
by Bligh and Dyer (Bligh and Dyer 1959). 100 mg of frozen fecal sample was 
homogenized in a mixture of 100 mL chloroform and 200 mL methanol for two 
minutes, before an additional 100 mL of chloroform was added and blended for 
thirty seconds, and another addition of 100 mL of water. The homogenate was 
filtered, and filtrate was transferred to a graduated cylinder and allowed to separate 
completely. The chloroform layer was recorded, and the alcoholic layer was 
removed. The chloroform, or lipid, extract was evaporated by a stream of nitrogen 
and dried in a desiccator overnight. The total fat was calculated using the formula 
given by Bligh and Dyer (1959).  
 
Histopathology 
After removal, colons were fixed in 10% neutral buffered formalin, paraffin 
embedded, sectioned longitudinally, and stained with hematoxylin and eosin. 
Sections were scored by Dr. Jesse Hostetter (Iowa State University, Department of 
Veterinary Pathology). Slides were viewed using an Olympus BX40 
research/diagnostic grade microscope (Center Valley, PA). 
The scoring system for histopathology used a scale from 0 to 5. A score of 0 
was given when the parameter was absent. A value of 1 was assigned when the 
parameter was at a low level. A score of 3 was a parameter that was common and 
present in most high power fields. A 4 was given for a severe parameter that was 
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present in multiple events. The highest value, 5, was when the parameter was so 
severe and frequent that the structure of the tissue was distorted or lost.  
Epithelial injury and ulceration was a measure of the damage to enterocytes 
in the lining of the gut or along the mucosal surface. The score was higher when 
ulceration was evident. Inflammation score indicated the density of inflammatory 
cells in the mucosa. A normal value for this score was 1, and in inflammation, the 
score increased. Edema signified tissue fluid expansion in the mucosa or submucosa. 
Stromal collapse indicated loss of glands in a region in which the mesenchymal 
stroma collapsed on itself. Gland hyperplasia specified excess proliferation in the 
tissue. Normal tissues had a score of around 0, and in inflammatory situations, the 
value increased. Goblet cell change was a marker of the decreases in goblet cell 
density in the lining of the glands. For this parameter, a value of 0 was a score for 
normal tissues, and increased with inflammation. 
 
Statistical Analysis 
Body weight and food intake were measured by mean values and ANOVA. 
Mean values were analyzed for fasting glucose, insulin, stool weight, stool 
consistency, stool weight per gram food intake, stool pH, and stool fat. Gut 
histopathology mean scores were analyzed. All values are reported as the mean ± 
standard deviation. All statistical analyses were performed using SPSS software 
(IBM), and p<0.05 and p<0.10 were considered to be significant.  
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RESULTS 
Body Weight 
No significant difference was observed for the change in body weight from 
baseline weight between all treatments for days 2, 3, 5, or 6 (Table 1A, Figure 1A). 
When separated by sex, no significant differences were observed between 
treatments for males on days 2, 3, 4, 5, or 6 (Table 1B, Figure 1B).  For female mice, 
no significant difference was observed for the first 4 days, day 6, 7, or the last 4 days 
(Table 1C. Figure 1C).  
C. rodentium infected groups fed the RS4 diet had a significant net loss in 
body weight compared to baseline on the first day (Table 1A, Figure 1A). When 
separated by sex, no significant difference between treatments was observed for 
day 1 for females (Table 1C. Figure 1C). However, a significant decrease in body 
weight from baseline was observed in male mice fed the RS4 diet compared to male 
mice fed the control diet (Table 1B, Figure 1B).   
On day 4, the uninfected mice on the RS4 diet showed a significant difference 
in body weight compared to the C. rodentium infected mice fed RS4. Uninfected mice 
fed RS4 did not differ from the uninfected mice on the control diet (Table 1A, Figure 
1A). This effect was not seen when body weights were analyzed by sex (Table 1B, 
1C, Figure 1B, and 1C).   
Uninfected female mice on the RS4 diet, on day 5, showed a significant 
difference in body weight change from baseline compared to the C. rodentium mice 
on the RS4 diet. The infected mice on the RS4 diet displayed an increase in body 
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weight from the baseline, whereas the uninfected mice had a decrease in body 
weight from baseline (Table 1A, Figure 1A). 
Both infected on the RS4 diet and the infected mice on the control diet 
exhibited a net loss in body weight on day 7 compared to the uninfected mice on the 
control diet (Table 1A, Figure 1A). Male mice experienced the same significant 
weight loss for both infected mice groups compared to the uninfected control diet 
fed mice (Table 1B, Figure 1B). Females, however, did not display a significant 
weight difference between treatments (Table 1C, Figure 1C). 
All mice showed a similar trend for changes in body weight on day 8 as for 
day 7, where there was a net loss in body weight for mice on both RS4 diets and the 
C. rodentium infected mice on the control diet. There was no difference in weight 
change between the two diets for uninfected mice (Table 1A, Figure 1A). When 
separated by sex, male mice that were infected tended to have a decrease in body 
weight compared to the uninfected mice on the control diet, although infected and 
uninfected mice on the RS4 diet were not significantly different from each other 
(Table 1B, Figure 1B). The female mice exhibited a decrease in body weight from 
baseline for infected and uninfected mice on the RS4 diet, and the infected mice on 
the control diet. The infected female mice on the RS4 diet had statistically similar 
body weights to both uninfected groups of female mice (Table 1C, Figure 1C). 
 The only mice that had a net increase in body weight on day 9 were the 
uninfected mice on the control diet. The infected mice on the control diet had a 
greater loss of body weight than the infected mice on the RS4 diet. The weight loss 
observed in both infected mouse groups, however, was not significantly different 
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than the body weight loss observed in uninfected mice on the RS4 diet (Table 1A, 
Figure 1A).  In male mice, overall, a net loss of body weight was observed in the 
infected mice as compared to the uninfected mice. However, in infected vs. 
uninfected male mice fed the RS4 diet, the difference was not significant (Table 1B, 
Figure 1B). Female mice displayed a net loss in body weight for all groups except the 
uninfected mice on the control diet, but the net loss in body weight for both RS4 fed 
female groups were not significantly different than the uninfected control mice 
(Table 1C, Figure 1C). 
 On day 10, similar changes in body weights were observed for both groups of 
mice on the RS4 diet, and the uninfected mice on the control diet. A significant 
decrease in body weight was observed for infected mice on the control diet (Table 
1A, Figure 1A). In male mice, the body weight changes on day 10 between C. 
rodentium infected mice on either diet were not statistically different, but the RS4 
fed infected mice displayed a similar change in body weight compared to the 
uninfected mice fed RS4 (Table 1B, Figure 1B). These trends were not observed in 
female mice (Table 1C, Figure 1C). All mice on day 11 exhibited a similar change in 
body weight as day 10, but infected male mice on the control diet had a significant 
loss in body weight as compared to all other treatments (Table 1A, 1B, Figure 1A, 
1B).  
 A significant loss of body weight was observed for infected mice on the 
control diet for both days 12 and 13 compared to the infected mice fed the RS4 diet. 
Uninfected mice fed the RS4 diet, showed a similar weight loss to the infected mice 
on the control diet (Table 1A, Figure 1A). Male mice did not display similarity 
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between the infected control mice and the uninfected RS4 mice. Instead, only the 
infected male mice on the control diet showed significantly lower body weight than 
other treatments (Table 1B, Figure 1B). These effects were not observed in the 
female mice.  
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Table 1A. Body weight change (g) from baseline by treatment.  
 
Infection Starch N Day 1 
(g) 
Day 2 
(g) 
Day 3 
(g) 
Day 4 
(g) 
Day 5 
(g) 
Day 6 
(g) 
Day 7 
(g) 
Day 8 
(g) 
Day 9 
(g) 
Day 10 
(g) 
Day 
11 (g) 
Day 12 
(g) 
Day 13 
(g) 
Uninfected Control 12 0.1 ± 
0.8ab 
-0.9 ± 
1.6 
0.2 ± 
1.0 
1.8 ± 
2.6ab 
0.5 ± 
1.1 
0.7 ± 
1.8 
0.9 ± 
1.6a 
1.2 ± 
1.2a 
1.2 ± 
1.4a 
0.8 ± 
1.5a 
0.1 ± 
1.4a 
0.3 ± 
1.5a 
1.0 ± 
1.5a 
Uninfected RS4 11 -1.0 ± 
0.3b 
-1.1 ± 
0.7 
-0.5 ± 
0.6 
-0.8 ± 
1.0b 
-0.8 ± 
1.1 
-0.6 ± 
1.5 
-0.8 ± 
1.3ab 
-0.6 ± 
1.1ab 
-1.0 ± 
1.3bc 
-0.7 ± 
2.5a 
-0.7 ± 
1.1a 
-1.1 ± 
1.2ab 
-1.1 ± 
1.6ab 
C. rod.  Control 6 0.2 ± 
0.2a 
0.6 ± 
1.1 
0.8 ± 
1.3 
0.2 ± 
1.1a 
0.0 ± 
1.1 
-0.2 ± 
1.2 
-1.1 ± 
1.0b 
-2.0 ± 
1.2b 
-2.7 ± 
1.3b 
-2.9 ± 
1.4b 
-2.9 ± 
1.6b 
-3.0 ± 
1.9b 
-2.5 ± 
2.3b 
C. rod.  RS4 6 -0.9 ± 
0.2b 
-0.8 ± 
1.1 
0.4 ± 
0.8 
0.3 ± 
0.8a 
0.3 ± 
1.0 
0.7 ± 
1.1 
-0.3 ± 
0.8b 
-0.8 ± 
0.8b 
-1.0 ± 
0.8c 
-0.6 ± 
0.8a 
-0.6 ± 
0.9a 
-0.7 ± 
1.0a 
-0.3 ± 
0.8a 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. rod.  
 
 
Table 1B. Male body weight change (g) from baseline by treatment.  
 
Infection Starch N Day 1 
(g) 
Day 2 
(g) 
Day 3 
(g) 
Day 4 
(g) 
Day 
5 (g) 
Day 
6 (g) 
Day 7 
(g) 
Day 8 
(g) 
Day 9 
(g) 
Day 10 
(g) 
Day 11 
(g) 
Day 12 
(g) 
Day 13 
(g) 
Uninfected Control 6 0.6 ± 
0.1a 
0.4 ± 
1.1 
0.9 ± 
0.6 
1.4 ± 
0.1 
1.2 ± 
0.5 
1.6 ± 
0.2 
1.9 ± 
0.2a 
1.8 ± 
0.9a 
1.7 ± 
0.7a 
1.6 ± 
0.7a 
1.0 ± 
0.7a 
1.1 ± 
1.2a 
1.6 ± 1.4a 
Uninfected RS4 5 -1.1 ± 
0.3b 
-1.0 ± 
0.2 
-0.6 ± 
0.8 
-0.2 ± 
0.7 
0.1 ± 
0.8 
0.3 ± 
1.7 
0.0 ± 
1.4ab 
0.3 ± 
0.8ac 
0.0 ± 
0.9ac 
0.7 ± 
3.1a 
0.1 ± 
0.3a 
-0.1 ± 
0.6a 
0.2 ± 1.0a 
C. rod.  Control 3 0.6 ± 
0.7a 
1.1 ± 
1.2 
0.7 ± 
0.9 
0.7 ± 
1.1 
0.5 ± 
0.8 
0.1 ± 
1.0 
-1.0 ± 
0.7b 
-2.2 ± 
0.9b 
-3.1 ± 
1.2b 
-3.7 ± 
1.1b 
-3.8 ± 
1.5b 
-3.9 ± 
1.4b 
-3.9 ± 
2.0b 
C. rod.  RS4 3 -1.2 ± 
0.8b 
-0.4 ± 
0.9 
0.2 ± 
0.9 
-0.2 ± 
1.0 
0.0 ± 
1.2 
0.2 ± 
0.9 
-0.7 ± 
0.9b 
-1.2 ± 
0.9bc 
-1.3 ± 
0.9bc 
-0.9 ± 
0.9ab 
-0.9 ± 
0.9a 
-1.3 ± 
1.1a 
-0.6 ± 
1.1a 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. rod. 
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Table 1C. Female body weight change (g) from baseline by treatment.  
 
Infection Starch N Day 1 
(g) 
Day 2 
(g) 
Day 3 
(g) 
Day 4 
(g) 
Day 5 
(g) 
Day 6 
(g) 
Day 7 
(g) 
Day 8 
(g) 
Day 9 
(g) 
Day 
10 (g) 
Day 
11 (g) 
Day 
12 (g) 
Day 
13 (g) 
Uninfected Control 6 -0.5 ± 
0.8 
-2.1 ± 
0.6 
-0.6 ± 
0.3 
2.3 ± 
4.1 
-0.1 ± 
1.3ab 
-0.2 ± 
2.4 
-1.6 ± 
0.4 
0.6 ± 
1.4a 
0.6 ± 
1.9a 
0 ± 1.7 -0.9 ± 
1.4 
-0.6 ± 
1.3 
0.4 ± 
1.5 
Uninfected RS4 6 -0.9 ± 
0.3 
-1.2 ± 
1.1 
-0.4 ± 
0.6 
-1.5 ± 
0.8 
-1.7 ± 
0.2b 
-1.4 ± 
0.4 
-0.2 ± 
1.9 
-1.5 ± 
0.5ab 
-2.1 ± 
0.1ab 
-2.0 ± 
0.6 
-1.5 ± 
1.0 
-2.1 ± 
0.8 
-2.3 ± 
0.7 
C. rod.  Control 3 -0.3 ± 
0.9 
0.0 ± 
0.9 
0.8 ± 
1.6 
-0.3 ± 
0.9 
-0.5 ± 
1.1ab 
-0.5 ± 
1.5 
-1.2 ± 
1.3 
-1.9 ± 
1.4b 
-2.2 ± 
1.3b 
-2.1 ± 
1.2 
-2.1 ± 
1.3 
-2.0 ± 
1.9 
-1.4 ± 
2.0 
C. rod.  RS4 3 -0.7 ± 
0.8 
-1.1 ± 
1.2 
0.5 ± 
0.7 
0.6 ± 
0.5 
0.5 ± 
0.9a 
1.2 ± 
1.1 
0.0 ± 
0.6 
-0.5 ± 
0.6ab 
-0.8 ± 
0.7ab 
-0.3 ± 
0.6 
-0.3 ± 
0.8 
-0.3 ± 
0.9 
0.0 ± 
0.7 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. rod. 
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Figure 1A. Body weight changes (g) over time by treatment.  
 
 
 
 
Figure 1B. Male body weight changes (g) over time by treatment. 
 
 
 
Figure 1C. Female body weight changes (g) over time by treatment.  
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Food Intake and Food Efficiency 
 No significant differences were observed in food intake for days 2, 3, 4, 5, 7, 
8, 9, and 10. On day 1, RS4 fed mice that were not infected with C. rodentium showed 
a significantly lower food intake than the infected mice. This difference was not 
observed compared to the uninfected control starch fed mice. Infected mice on the 
control diet had significantly less food intake on day 6 than did the uninfected mice. 
Infected mice on the RS4 diet exhibited less food intake compared to the uninfected 
mice on the RS4 diet, but this was not observed compared to both groups fed 
control diet. On days 11 and 12, C. rodentium infected mice on the control diet had 
significantly less food intake compared to the infected mice on the RS4 diet, but no 
significant difference was observed between food intake for those mice and the 
uninfected groups. The RS4 fed mice that were infected with C. rodentium had an 
increased intake compared to the infected mice on the control diet, but no 
significant difference compared to uninfected mice. On the last day, there was a 
significant difference between food intakes for both RS4 diets, where the infected 
mice displayed a higher intake than those that were not infected (Table 2A, Figure 
2).  
In male mice, infected mice on the RS4 diet had a significantly decreased food 
intake compared to the uninfected mice fed the control diet on days 1 and 3. On day 
6, a significant difference was observed in food intake between the uninfected RS4 
fed mice and the infected control diet fed mice. On day 11, uninfected RS4 fed mice 
displayed a significantly lowered food intake compared to the RS4 fed infected mice. 
(Table 2B). In females, infected control fed mice showed a significantly lowered food 
intake on day 6 compared to uninfected control fed mice (Table 2C).  
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Food efficiency ratio is a measure of food intake and body weight output, or 
the mass gained in grams per gram of food intake. No significant difference was 
observed for food efficiency ratio for days 1-6 and 10-13. On day 7, no significant 
differences were observed when analysis was done without separating sexes (Table 
3A, Figure 3A). Upon separation of sexes, males and females showed significantly 
different food efficiency in the uninfected mice on the control diet compared to all 
treatments (Table 3B, 3C, Figure 3B, 3C). On day 8, uninfected mice on the control 
diet showed a significantly higher food efficiency ratio than the infected mice on 
both diets (Table 3A, Figure 3A). In females, the uninfected RS4 fed mice had 
significantly higher food efficiency ratios than the infected mice, but this was not 
significantly different from the uninfected mice fed the control diet (Table 3C, Figure 
3C). The same result for both sexes together on day 8 was also observed on day 9 
(Table 3A, Figure 3A).   
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Table 2A. Food intake (g/day) by treatment.  
 
Infection Starch N Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 
10 
Day 11 Day 12 Day 13 
Uninfected Control 6 4.9 ± 
1.8ab 
6.5 ± 
1.3 
7.6 ± 
1.3 
8.6 ± 
0.6 
7.2 ± 
3 
6.4 ± 
1.3ab 
5.5 ± 
2 
7 ± 
1.4 
5.2 ± 
1.4 
8.9 ± 
2 
4.4 ± 
2.3ab 
7.1 ± 
1ab 
8 ± 
2.4ab  
Uninfected RS4 6 3.7 ± 
0.9b 
5.8 ± 
1.5 
5.8 ± 
0.9 
8.7 ± 
1 
5.8 ± 
0.8 
6.7 ± 
0.7b 
4.7 ± 
1.1 
6 ± 
0.5 
3.7 ± 
0.8 
9 ± 
1.1 
5.5 ± 
1.5ab 
5.5 ± 
1.7ab  
4.8 ± 2b 
C. rod.  Control 12 6.7 ± 
1.6a 
5.6 ± 
1.4 
5.7 ± 
1.6 
9 ± 
1.5 
6.4 ± 
2 
4.6 ± 
1.1c 
4.4 ± 
1.8 
5.8 ± 
2.5 
4.4 ± 
2.5 
8 ± 
3.2 
3.4 ± 
1.6a 
5.5 ± 
2.4a 
6.7 ± 
2.2ab  
C. rod.  RS4 11 5.6 ± 
1.5a 
5.5 ± 
1.7 
5.3 ± 
1.5 
8.5 ± 
4 
7.6 ± 
2.4 
5.5 ± 
0.9ac 
5.1 ± 
1 
5.2 ± 
1.6 
3.3 ± 
1.6 
6.5 ± 
2 
8.3 ± 
4.1b 
7.9 ± 
1.6b 
8 ± 2.5a  
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. rod. 
 
 
 
 
 
Table 2B. Food intake (g/day) for male mice by treatment.  
Infection Starch N Day 
1 
Day 
2 
Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 
10 
Day 
11 
Day 
12 
Day 13 
Uninfected Control 3 5.9 ± 
1.6a 
6.7 ± 
1.6 
7.9 ± 
1.4a 
8.9 ± 
0.8 
8.4 ± 
4.0 
5.4 ± 
0.4ab 
6.5 ± 
1.7 
6.5 ± 
0.7 
5.3 ± 
1.9 
9.2 ± 
2.8 
5.2 ± 
1.3ab 
5.5 ± 
1.9 
7.0 ± 
1.0 
Uninfected RS4 3 3.8 ± 
1.4ab 
5.2 ± 
1.5 
5.9 ± 
0.7ab 
8.8 ± 
0.2 
6.3 ± 
0.6 
6.8 ± 
0.8a 
4.5 ± 
0.7 
6.1 ± 
0.5 
3.7 ± 
0.3 
8.6 ± 
1.2 
0.8 ± 
7.7a 
6.4 ± 
2.1 
4.5 ± 
3.2 
C. Rod.  Control 6 7.5 ± 
1.6ab 
5.4 ± 
1.5 
5.6 ± 
1.4ab 
9.5 ± 
1.0 
7.0 ± 
0.7 
4.0 ± 
1.1b 
4.4 ± 
2.1 
4.7 ± 
2.3 
4.1 ± 
1.6 
6.9 ± 
2.4 
3.0 ± 
2.6ab 
4.4 ± 
1.7 
6.0 ± 
2.2 
C. Rod.  RS4 5 4.9 ± 
1.6b 
5.4 ± 
2.2 
4.7 ± 
1.4b 
11.2 ± 
5.5 
7.0 ± 
1.6 
5.1 ± 
0.6ab 
5.0 ± 
0.9 
4.5 ± 
1.3 
3.4 ± 
1.1 
7.0 ± 
1.8 
10.4 ± 
1.9b 
7.2 ± 
1.2 
6.8 ± 
3.0 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. rod. 
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Table 2C. Female food intake (g/day) by treatment.  
 
Infection Starch N Day 
1 
Day 2 Day 
3 
Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 
10 
Day 
11 
Day 
12 
Day 
13 
Uninfected Control 3 3.8 ± 
1.4 
6.3 ± 
1.3 
7.3 ± 
1.3 
8.4 ± 
0.2 
6.0 ± 
1.2 
7.4 ± 
1.1a 
4.6 ± 
2.0 
7.6 ± 
1.9 
5.1 ± 
1.0 
8.7 ± 
1.6 
3.5 ± 
3.0 
8.7 ± 
1.7 
9.2 ± 
3.2 
Uninfected RS4 3 3.6 ± 
0.3 
6.5 ± 
1.5 
5.8 ± 
1.2 
8.6 ± 
1.5 
5.3 ± 
0.7 
6.6 ± 
0.8ab 
4.8 ± 
1.6 
5.8 ± 
0.6 
3.7 ± 
1.1 
9.3 ± 
0.9 
4.9 ± 
0.9 
4.5 ± 
0.3 
4.9 ± 
0.3 
C. Rod.  Control 6 5.9 ± 
1.4 
5.7 ± 
1.4 
5.8 ± 
2.0 
8.5 ± 
1.8 
5.8 ± 
2.8 
5.2 ± 
0.7b 
4.4 ± 
1.7 
6.9 ± 
2.4 
4.7 ± 
3.3 
9.1 ± 
3.6 
3.5 ± 
1.4 
6.7 ± 
2.7 
7.4 ± 
2.2 
C. Rod.  RS4 6 6.2 ± 
1.3 
5.6 ± 
1.2 
5.9 ± 
1.6 
8.2 ± 
1.4 
8.1 ± 
2.9 
5.8 ± 
1.0ab 
5.2 ± 
1.2 
5.7 ± 
1.8 
3.1 ± 
2.2 
6.0 ± 
2.2 
6.5 ± 
3.0 
8.5 ± 
1.8 
9.0 ± 
1.7 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. rod. 
 
 
 
 
Table 3A. Food efficiency ratio (g food intake/g weight gained/day) by treatment. 
 
Infection Starch N Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 
10 
Day 
11 
Day 
12 
Day 
13 
Uninfected Control 6 0.06 ± 
0.05 
0.02 ± 
0.03 
0.15 ± 
0.14 
0.20 ± 
0.34  
0.05 ± 
0.06  
0.05 ± 
0.05  
0.08 ± 
0.13 
0.07 ± 
0.06a 
0.02 ± 
0.03a 
0.00 ± 
0.01 
0.00 ± 
0.00 
0.04 ± 
0.04 
0.09 ± 
0.03 
Uninfected RS4 6 0.00 ± 
0.00 
0.04 ± 
0.05 
0.14 ± 
0.22 
0.02 ± 
0.03 
0.05 ± 
0.07 
0.06 ± 
0.08 
0.01 ± 
0.03 
0.04 ± 
0.05ab 
0.01 ± 
0.02ab 
0.11 ± 
0.15 
0.19 ± 
0.24 
0.01 ± 
0.02 
0.03 ± 
0.05 
C. rod. Control 12 0.05 ± 
0.07 
0.11 ± 
0.15 
0.08 ± 
0.11 
0.02 ± 
0.04 
0.02 ± 
0.03 
0.03 ± 
0.05 
0.02 ± 
0.06 
0.00 ± 
0.00b 
0.01 ± 
0.02b 
0.01 ± 
0.03 
0.12 ± 
0.17 
0.08 ± 
0.19 
0.08 ± 
0.11 
C. rod. RS4 11 0.01 ± 
0.02 
0.12 ± 
0.14 
0.25 ± 
0.28 
0.02 ± 
0.05 
0.03 ± 
0.03 
0.11 ± 
0.13 
0.00 ± 
0.00 
0.01 ± 
0.02b 
0.01 ± 
0.03b 
0.12 ± 
0.03 
0.03 ± 
0.05 
0.03 ± 
0.05 
0.11 ± 
0.15 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. rod. 
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Table 3B. Male food efficiency ratio (g food intake/g weight gained/day) by treatment. 
 
Infection Starch N Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 
10 
Day 
11 
Day 
12 
Day 
13 
Uninfected Control 3 0.10 ± 
0.02 
0.04 ± 
0.03 
0.08 ± 
0.10 
0.06 ± 
0.06 
0.02 ± 
0.03 
0.07 ± 
0.06 
0.05 ± 
0.01a 
0.04 ± 
0.03 
0.01 ± 
0.01 
0.01 ± 
0.01 
0.00 ± 
0.00 
0.03 ± 
0.03  
0.07 ± 
0.02 
Uninfected RS4 3 0.00 ± 
0.00 
0.04 ± 
0.07 
0.08 ± 
0.08 
0.04 ± 
0.03 
0.05 ± 
0.07 
0.06 ± 
0.06 
0.05 ± 
0.01b 
0.04 ± 
0.03 
0.01 ± 
0.02 
0.19 ± 
0.19 
0.19 ± 
0.23 
0.01 ± 
0.03 
0.05 ± 
0.06 
C. rod. Control 6 0.06 ± 
0.07 
0.15 ± 
0.21 
0.04 ± 
0.08 
0.04 ± 
0.04  
0.03 ± 
0.05  
0.00 ± 
0.00 
0.00 ± 
0.00b 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.20 ± 
0.22 
0.12 ± 
0.28 
0.05 ± 
0.05 
C. rod. RS4 5 0.00 ± 
0.15 
0.18 ± 
0.15 
0.18 ± 
0.25 
0.00 ± 
0.00 
0.03 ± 
0.04 
0.08 ± 
0.10 
0.00 ± 
0.00b 
0.00 ± 
0.01 
0.02 ± 
0.04 
0.08 ± 
0.11 
0.01 ± 
0.02 
0.05 ± 
0.07 
0.20 ± 
0.20 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. rod. 
 
 
 
 
Table 3C. Female food efficiency ratio (g food intake/g weight gained/day) by treatment. 
 
Infection Starch N Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 
10 
Day 
11 
Day 
12 
Day 
13 
Uninfected Control 3 0.02 ± 
0.04 
0.00 ± 
0.00 
0.22 ± 
0.15 
0.34 ± 
0.48 
0.07 ± 
0.07 
0.04 ± 
0.05 
0.11 ± 
0.19a 
0.11 ± 
0.06ab 
0.03 ± 
0.04 
0.00 ± 
0.00 
0.00 ± 
0.00 
0.04 ± 
0.05 
0.11 ± 
0.04 
Uninfected RS4 3 0.00 ± 
0.00 
0.05 ± 
0.04 
0.19 ± 
0.33 
0.00 ± 
0.04 
0.05 ± 
0.09 
0.05 ± 
0.05 
0.02 ± 
0.01b 
0.02 ± 
0.03a 
0.00 ± 
0.00 
0.03 ± 
0.10 
0.20 ± 
0.28 
0.00 ± 
0.00 
0.00 ± 
0.00 
C. rod. Control 6 0.03 ± 
0.07 
0.07 ± 
0.06 
0.12 ± 
0.12  
0.00 ± 
0.01 
0.01 ± 
0.02 
0.05 ± 
0.06 
0.04 ± 
0.08b 
0.00 ± 
0.00b 
0.02 ± 
0.03 
0.02 ± 
0.03 
0.04 ± 
0.05 
0.05 ± 
0.06  
0.12 ± 
0.15 
C. rod. RS4 6 0.01 ± 
0.02 
0.07 ± 
0.12 
0.31 ± 
0.30 
0.04 ± 
0.06 
0.02 ± 
0.03 
0.14 ± 
0.16 
0.00 ± 
0.00b 
0.01 ± 
0.02b 
0.00 ± 
0.00 
0.15 ± 
0.17 
0.04 ± 
0.06 
0.02 ± 
0.01 
0.04 ± 
0.03 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. rod. 
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Figure 2. Food intake (g/day) over time by treatment.  
 
 
 
Figure 3A. Food efficiency ratio over time by treatment. 
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Figure 3B. Male food efficiency ratio over time by treatment. 
 
 
 
Figure 3C. Female food efficiency ratio over time by treatment. 
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Stool Consistency 
 No significant difference was observed for stool consistency for day 1, 3, and 4. 
Uninfected mice on the RS4 diet displayed a significantly lower stool consistency than the 
other uninfected group. On day 5, 7, 8, 11, and 13, C. rodentium infected mice had 
significantly lower stool consistencies than the uninfected groups. However, on day 5, the 
stool consistency for uninfected mice on the RS4 diet was similar to those of the infected 
mice. The lowest stool consistency observed occurred on day 9, where the infected mice 
on the control diet displayed a stool consistency of 1.1 ± 0.3.  The infected mice on the 
RS4 diet never reached a consistency as low as those on the control diet, where 1.8 ± 1.2 
was the lowest stools core reached. After day 7, stool consistency for infected mice on the 
RS4 diet increased through day 14. On day 14, although not statistically similar to the 
uninfected mice, the infected mice on the RS4 diet displayed an increased in stool weight 
that was significantly higher than the infected mice on the control diet (Table 4, Figure 
4A, 4B).  
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Table 4. Stool consistency (grade 1-5) for all treatments.  
 
Infection Starch N Day 
1 
Day 
2 
Day 
3 
Day 
4 
Day 
5 
Day 
6 
Day 7 Day 
8 
Day 
9 
Day 
10 
Day 
11 
Day 
12 
Day 
13 
Day 
14 
Uninfected Control 6 4.8 ± 
0.4 
5b 4.8 ± 
0.4 
4.7 ± 
0.5 
5b 5b 5b 5b 5c 5c 5b 5c 5b 5c 
Uninfected RS4 6 4.5 ± 
0.5 
3.8 ± 
0.8c 
4.5 ± 
0.5 
4.5 ± 
0.5 
4.7 ± 
0.5ab 
4.3 ± 
0.8c 
4.7 ± 
0.8b 
5b 4.7 ± 
0.5c 
5c 5b 5c 5b 5c 
C. rod. Control 12 4.6 ± 
0.8 
4.8 ± 
0.4ab 
4.5 ± 
0.5 
4.5 ± 
0.9 
4.3 ± 
1.1a 
2.3 ± 
1.2a 
2.7 ± 
1.2a 
1.8 ± 
1.3a 
1.1 ± 
0.3a 
1.3 ± 
0.6a 
1.8 ± 
1.2a 
1.6 ± 
0.9a 
2.6 ± 
1.6a 
1.8 ± 
1.1a 
C. rod. RS4 11 4.6 ± 
0.5 
4.6 ± 
0.5ac 
4.6 ± 
0.5 
4.4 ± 
0.5 
4.1 ± 
0.9a 
3.1 ± 
1ac 
1.8 ± 
1.2a 
2.4 ± 
1.4a 
2.7 ± 
1.3b 
2.7 ± 
1.3b 
3 ± 
1.2a 
3 ± 
1.2b 
3.1 ± 
1.3a 
3.4 ± 
1.2b 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. 
rod. 
 
 
Figure 4A. Stool Consistency (grade 1-5) for all treatments. 
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Figure 4B. Stool consistency grading for Day 1, 7, and 14. 
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Stool Weight, Stool pH, Stool Fat, and Water and Fat Content of Stool 
No significant differences were observed in stool weight for the last two days of 
the experiment. The ratio of stool weight to food intake also showed no significant 
differences. No significant differences were observed for water content of stool, which 
was recorded as a measure of diarrhea. No significant differences were observed for fat 
content of the stool (Table 5).  
For stool pH, mice fed the RS4 diet had statistically similar results for pH. The 
values for pH for RS4 fed mice were significantly lower than the C. rodentium infected 
mice on the control diet. However, the pH value for the RS4 fed mice was not significantly 
different from the uninfected mice fed the control diet (Table 5, Figure 5).  
 
Figure 5. Stool pH by treatment and diet.  
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Table 5. Stool weight, stool weight to food intake ratio, stool pH, water content of stool, and fat content of stool results.  
 
Infection Starch N Day 12 
Stool 
Weight 
(g) 
Day 13 
Stool 
Weight 
(g) 
Day 12-13 Stool 
Weight/ 
Day 13-14 
Stool Weight/ 
Stool 
pH 
Water 
Content of 
Stool 
Stool Fat 
per gram 
Stool Food Intake Food Intake 
Uninfected Control 6 0.25 ± 
0.15 
0.48 ± 
0.52 
0.039 ± 0.028 0.07 ± 0.086 7.5 ± 
0.4ab 
0.6 0.14 ± 0.04 
Uninfected RS4 6 0.3 ± 
0.17 
0.15 ± 
0.08 
0.061 ± 0.04 0.06 ± 0.095 7.5 ± 
0.3b 
0.6 ± 0.3 0.29 ± 0.34 
C. rod. Control 12 0.17 ± 
0.16 
0.22 ± 
0.13 
0.035 ± 0.043 0.032 ± 0.022 7.9 ± 
0.3a 
0.7 ± 0.1 0.18 ± 0.17 
C. rod. RS4 11 0.3 ± 
0.13 
0.57 ± 
0.84 
0.038 ± 0.015 0.075 ± 0.088 7.3 ± 
0.4b 
1.3 ± 2.5 0.14 ± 0.06 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is 
abbreviated as C. rod. 
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Serum Glucose, Insulin, and Lipids 
 No significant differences were observed for fasting serum glucose, insulin, total 
cholesterol, and non-HDL Cholesterol (Table 6, Figure 6A, 6B, 6C, 6E). Infected mice on the 
control starch diet displayed a lower fasting HDL cholesterol concentration, at 75.9 ± 9.1 
mmol/L, than the respective mice on the control starch diet, which had serum HDL 
concentrations of 109.2 ± 11.8 mmol/L. Serum HDL concentrations in resistant starch fed 
mice did not show any significant differences from other treatments (Table 6, Figure 6D). 
Infected mice on the control starch diet displayed significantly lower triglyceride 
concentrations than the infected mice on the RS4 diet. This difference was not seen 
between diets in the uninfected mice (Table 6, Figure 6F). Table 6 summarizes the serum 
concentrations of glucose, insulin, and lipids. 
 
Figure 6. Fasting serum A. Glucose (mmol/L), B. Insulin (pmol/L), C. Total Cholesterol 
(mmol/L), D. HDL-Cholesterol (mmol/L), E. Non-HDL Cholesterol (mmol/L), and F. 
Triglycerides (mmol/L) 
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Table. 6 Fasting serum glucose, insulin, and lipid by treatment.  
 
Infection Starch N Glucose 
(mmol/L) 
Insulin 
(pmol/L) 
Total Cholesterol 
(mmol/L) 
HDL Cholesterol 
(mmol/L) 
Non-HDL 
Cholesterol 
(mmol/L) 
Triglycerides 
(mmol/L) 
Uninfected Control 6 9.46 ± 3.3 53.7 ± 33 138.5 ± 15.1 109.2 ± 11.8a 36.5 ± 6.1 1.21 ± 0.19ab 
Uninfected RS4 6 9.46 ± 1.8 43.4 ± 
16.7 
125.6 ± 10.5 108.9 ± 7.1ab 31.0 ± 2.9 1.17 ± 0.07ab 
C. rod. Control 12 9.72 ± 2.4 43.8 ± 
28.8 
113.8 ± 10.0 75.9 ± 9.1b 28.7 ± 9.2 1.02 ± 0.13b 
C. rod. RS4 11 10.9 ± 2.5 55.4 ± 
20.6 
128.7 ± 7.8 95.1 ± 9.4ab 19.8 ± 4.2 1.82 ± 0.22a 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as 
C. rod. 
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Histopathology 
 No significant differences between treatments and diets were observed for stromal 
collapse (Table 7A, Figure 7E). Mucosal height, epithelial injury/ulceration, gland 
hyperplasia, and goblet cell change was significantly increased in C. rodentium infected 
mice (Table 7A, Figure 7A, 7B, 7F, 7G). No significant differences were observed between 
diet treatments for those parameters. Edema was significantly lower in C. rodentium 
infected mice than in uninfected mice (Table 7A, Figure 7D). Inflammation score was 
significantly higher in infected mice on the control starch diet compared to the uninfected 
mice on the respective diet. However, there was no statistical difference between 
inflammation score between both RS4 fed groups (Table 7A, Figure 7C). When statistical 
analysis was completed at significance level of 0.10, infected mice fed the RS4 diet 
displayed significant improvements in ulceration/epithelial injury, gland hyperplasia, and 
goblet cell density compared to the infected mice fed the control diet; this, was 
significantly lower than the scores for these parameters for uninfected mice (Table 7B). 
When separated by gender, no significant difference was observed for mucosal 
height or stoma collapse for both genders (Figure 7b, 7c). C. rodentium males fed the 
control diet displayed a significantly higher ulceration, gland hyperplasia, inflammation, 
and goblet cell change compared to the control starch fed and resistant starch fed 
uninfected mice. C. rodentium infected males fed the resistant starch diet displayed similar 
results, however for ulceration, the group exhibited a significantly lowered score 
compared to the C. rodentium infected control fed group. Uninfected male mice on the 
resistant starch diet scored significantly higher for edema compared to all other 
treatments. For females, C. rodentium mice displayed significantly higher goblet cell 
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change and gland hyperplasia scores compared to uninfected mice. For ulceration, 
uninfected mice scored significantly lower compared to the infected mice, however, there 
was no significant difference in score between the uninfected mice fed the control diet and 
the infected mice fed the resistant starch diet. For edema, infected mice exhibited 
significantly lower scores compared to the uninfected mice.  
 101 
Table 7A. Histopathology results for all treatments, significance level set at 0.05.  
Infection Starch N Mucosal 
Height 
Ulceration/ Inflammation 
score 
Edema Stromal 
Collapse 
Gland 
Hyperplasia 
Goblet Cell 
Change epithelial 
injury 
Uninfected Control 6 4.67 ± 0.52b 0.2 ± 0.4b 2 ± 0.6b 0.8 ± 
0.8b 
0 0.3 ± 0.5b 0b 
Uninfected RS4 6 4.83 ± 0.41b 0b 2.3 ± 0.8bc 0.8 ± 
0.4b 
0 0.7 ± 0.5b 0b 
C. rod. Control 12 6.45 ± 0.93a 2.4 ± 0.8a 3.8 ± 0.4a 0a 0.27 ± 0.47 3.4 ± 0.8a 2.8 ± 0.6a 
C. rod. RS4 11 6.27 ± 1.35a 1.4 ± 1.3a 3.3 ± 0.6ac 0a 0.09 ± 0.3 2.5 ± 0.8a 1.4 ± 1.3a 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as 
C. rod. 
 
 
 
Table 7B. Histopathology results for all treatments, significance level set at 0.10. 
Infection Starch N Mucosal 
Height 
Ulceration/ Inflammation 
score 
Edema Stromal 
Collapse 
Gland 
Hyperplasia 
Goblet Cell 
Change epithelial 
injury 
Uninfected Control 6 4.67 ± 0.52b 0.2 ± 0.4c 2 ± 0.6b 0.8 ± 
0.8b 
0 0.3 ± 0.5c 0c 
Uninfected RS4 6 4.83 ± 0.41b 0c 2.3 ± 0.8b 0.8 ± 
0.4b 
0 0.7 ± 0.5c 0c 
C. Rod. Control 12 6.45 ± 0.93a 2.4 ± 0.8a 3.8 ± 0.4a 0a 0.27 ± 0.47 3.4 ± 0.8a 2.8 ± 0.6a 
C. Rod. RS4 11 6.27 ± 1.35a 1.4 ± 1.3b 3.3 ± 0.6a 0a 0.09 ± 0.3 2.5 ± 0.8b 1.4 ± 1.3b 
* Treatments at a time point bearing a different letter are significantly different, p <0.10; Citrobacter rodentium is abbreviated as C. 
rod. 
 
 102 
 
Table 7C. Histopathology results for males, all treatments.  
Infection Starch N Mucosal 
Height 
Ulceration/ Inflammation 
score 
Edema Stromal 
Collapse 
Gland 
Hyperplasia 
Goblet Cell 
Change epithelial 
injury 
Uninfected Control 3 4.67 ± 0.58 0a 1.7 ± 0.6a 0.3 ± 
0.6a 
0 0.3 ± 0.6a 0a 
Uninfected RS4 3 4.67 ± 0.58 0a 1.7 ± 0.6a 1.0 ± 
0.0b 
0 0.3 ± 0.6a 0a 
C. Rod. Control 5 6.20 ± 0.40 2.3 ± 1.0b 3.8 ± 0.5b 0a 0.40 ± 0.55 3.2 ± 0.9b 2.6 ± 0.6b 
C. Rod. RS4 5 6.00 ± 1.00 0.4 ± 0.5a 3.0 ± 0.7b 0a 0 2.0 ± 0.7b 0.4 ± 0.5a 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. 
rod. 
 
 
 
 
 
Table 7D. Histopathology results for females, all treatments.  
Infection Starch N Mucosal 
Height 
Ulceration/ Inflammation 
score 
Edema Stromal 
Collapse 
Gland 
Hyperplasia 
Goblet Cell 
Change epithelial 
injury 
Uninfected Control 3 4.67 ± 0.58 0.3 ± 0.8ac 2.3 ± 0.6a 1.3 ± 
0.6a 
0 0.3 ± 0.6a 0a 
Uninfected RS4 3 5.00 ± 0.00 0a 3.0 ± 0.0ab 0.7 ± 
0.6a 
0 1.0 ± 0.0a 0a 
C. Rod. Control 6 6.67 ± 1.21 2.5 ± 0.8b 3.8 ± 0.4b 0b 0.17 ± 0.41 3.3 ± 0.8b 3.0 ± 0.6b 
C. Rod. RS4 6 6.50 ± 1.38 2.2 ± 1.2bc 3.5 ± 0.6b 0b 0.17 ± 0.41 3.0 ± 0.6b 2.2 ± 1.2b 
* Treatments at a time point bearing a different letter are significantly different, p <0.05; Citrobacter rodentium is abbreviated as C. 
rod. 
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Figure 7a. Histopathology results.  
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Figure 7b. Male Histopathology.  
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Figure 7c. Female Histopathology. 
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DISCUSSION 
Body Weight Changes and Food Intake 
 In the uninfected mice, we expected to see a lowered food intake in the mice 
fed the RS4 diet compared to the mice fed the control diet.  Brites et al (2011) fed 36 
male Wistar rats four diets consisting of wheat bread, RS-wheat bread, maize bread, 
or RS-maize bread for 16 days. Rats fed RS-wheat bread displayed significantly 
lowered food intake, stool pH, and serum glucose. RS-maize bread fed rats exhibited 
reduced body weight gain, stool pH, and total cholesterol level.  The results 
concluded that RS supplementation in diets significantly reduce food intake (Brites, 
Trigo et al. 2011). Aziz et al (2009) performed a three-week study consisting of 46 
male Sprague-Dawley rats fed a non-energy restricted high amylose diet or a non-
energy restricted high amylopectin diet. The high amylose diet fed rats displayed a 
significantly lower energy intake and weight gain. Aziz et al also concluded that a RS 
diet reduced energy intake in obese rats (Aziz, Kenney et al. 2009). Bodinham et al 
(2010) also completed a short-term study with twenty young adult males on the 
effects of a dose of 48g RS on food intake for 24 hours post meal, and experienced a 
similar result; there was reduced food intake during the 24 hours post RS meal 
(Bodinham, Frost et al. 2010). This correlates with the uninfected mice, on day 13, 
experienced a significantly lowered food intake than the mice on the control diet.  
 We did not see this effect in the C. rodentium infected mice. Food intake was 
statistically similar to the intake observed in the uninfected mice fed the control diet 
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on days 1, 6, 11, 12, and 13. We also did not see the effect of lowered food intake in 
uninfected mice until the last day of the study.  
Due to our hypothesis of lowered food intake, we also expected to see lower 
body weights in mice fed the RS diet. This hypothesis was not observed in either 
group of RS4 fed mice. This result could be attributed to the lack of reduced food 
intake in mice fed the RS4 diet, as we did not see a significantly lowered food intake 
until the final day of the study.  
 We expected that the C. rodentium treatment would cause severe weight loss 
in our mice. Weight loss in the C. rodentium infected mice is potentially due to the 
disruption of intestinal barrier function, leading to malabsorption of nutrients, 
ultimately resulting in weight loss (Hodges and Gill 2010). Other potential reasons 
for weight loss in the C. rodentium model include loss of nutrients in stool or 
increased energy expenditure. Rigaud et al (1994) analyzed weight loss in 30 
Crohn’s disease patients, which is an inflammatory bowel disease with symptoms 
similar to those of the C. rodentium model. The study concluded that weight loss in 
this type of disease may be due to a decrease in food intake (Rigaud, Angel et al. 
1994). In the infected mice, we observed an initial decrease in body weight for the 
mice fed the control starch diet, starting at day 6. This continued through day 13, 
where weight loss was significantly lower compared to the uninfected mice fed the 
control diet. This was not observed in the infected mice fed the RS4 diet. Body 
weights were maintained throughout the study, and were not significantly altered 
from the uninfected mice. When separated by sex, males showed similar results, 
where the infected mice fed the control starch diet had significant weight loss 
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compared to all other treatments. We did not, however, see a significant weight loss 
in the infected mice fed the control diet. Females showed similar body weight 
changes throughout the study for all treatments. This can be attributed to the lack of 
a significant difference in food intake for female mice, in all treatments.  
 The results that body weight and food intake did not significantly change in 
RS4 fed mice infected with C. rodentium suggests that a resistant starch 
supplemented diet could potentially protect from the weight loss associated with 
colitis, or other inflammatory bowel diseases.  
 
Stool Consistency 
We hypothesized that mice inoculated with C. rodentium would have a large 
decrease in stool consistency, but those on the RS4 diet would have a less severe 
diarrheal response than those on the control diet. The decline in stool consistency 
for those infected started at about day 6 and 7. After the initial decrease, the infected 
mice on the RS4 diet experienced a steady increase in stool consistency (Figure 4A) 
By the final day, the infected mice on the RS4 diet had a significantly higher stool 
consistency (~3.5) than the infected mice on the control diet (~2), confirming our 
hypothesis (Figure 4B). The infected mice on the RS4 diet, however, did still have a 
significantly lower stool consistency than non-infected mice. This suggests that the 
RS mitigated diarrhea, but did not completely improve upon stool consistency. 
RS can improve stool consistency in a number of ways. It has a high water 
holding capacity, allowing it to isolate water from the liquid diarrhea. Absorption of 
the water in diarrhea by RS increases stool bulk, which would contribute to our 
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higher stool consistency observed in C. rodentium infected mice on the RS4 diet 
(Bosaeus 2004). 
Production of short chain fatty acids (SCFAs) is another contributing factor 
for the decrease in diarrhea due to consumption of RS. Through fermentation in the 
large intestine, short chain fatty acids are produced, which decrease the pH in the 
gut. This decrease in pH, along with the SCFAs can stimulate water and sodium 
absorption in the large intestine. Increased water absorption increases stool 
consistency, and ultimately decreases the diarrhea associated with the C. rodentium 
infection (Soral-Smietana and Wronkowska 2004). In our study, however, fecal 
SCFAs were not measured, so this correlation could not be confirmed.  
Ramakrishna et al (2000) discovered that the addition of RS in oral 
rehydration therapy reduces fluid loss in stool and shortens the duration of diarrhea 
in adults and children. 48 adolescents were randomly assigned to glucose based oral 
rehydration therapy (n=16), glucose oral rehydration therapy with 50 g/L rice flour 
(n=16), or glucose oral rehydration therapy with 50 g/L high amylose maize starch 
(n=16, and stool weight and transit time to first stool were measured every 12 
hours for 48 total hours (Ramakrishna, Venkataraman et al. 2000). In another study, 
Ramakrishna et al (2008) subjected 50 adult males to hypo-osmolar oral 
rehydration solution with or without 50g/L of high amylose maize starch 
substituted for glucose. Parameters were measured for 48 hours, which included 
consistency and weight of stool. Stool consistency was based upon the Bristol scale. 
Ramakrishna et al found that oral rehydration of RS reduced diarrhea diarrheal 
 110 
duration, leading to the belief that RS could be used as a treatment for diarrheal 
diseases, including cholera (Ramakrishna, Subramanian et al. 2008).  
We found that although there was a significant increase in stool consistency 
with C. rodentium infected mice fed the RS4 diet compared to the infected mice on 
the control diet, the stool consistency in the infected mice fed the RS4 diet was still 
significantly lower than the uninfected mice. The results found in this study, along 
with the results found in the literature, can contribute to the indication that RS can 
improve diarrhea, making it a useful method of treatment for diarrheal disease.  
  
Stool pH  
 A significantly lowered stool pH was observed in the C. rodentium infected 
mice fed the RS4 diet compared to the infected mice fed the control diet. Lowered 
pH in the stool suggests a lowered gut pH, which indicates a higher level of SCFA 
presence. This higher level of SCFAs indicated by the stool pH can promote ion 
uptake and water uptake, therefore decreasing diarrhea. The observation that the 
RS4 diet decreased pH in the stool corresponded with the increased stool 
consistency observed in RS4 fed infected mice.  
We found that in infected mice, the RS4 fed group had a significantly lower 
stool pH compared to those fed the control diet. These results indicate that the RS 
can mitigate diarrhea through a lowered gut pH, which may be attributed to SCFA 
production through fermentation of the RS4 in the large intestine.  
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Serum Glucose, Insulin and Lipids 
 We hypothesized that a RS4 supplemented diet would decrease insulin and 
glucose responses in our mice. Resistant starches are associated with a higher 
composition of amylose, which contributes to the indigestibility. The chain-like 
nature of amylose causes glucose to be released slowly, causing less glucose to be 
absorbed in the small intestine. The glucose response of an organism, in turn, would 
decrease in conjunction, due to the lowered availability of free glucose. A lowered 
insulin response would be observed as well, because the lessened availability of free 
glucose would have a lowered stimulation on insulin. The stability of glucose and 
insulin response due to resistant starch would lead to stability in body weight 
(Nugent 2005, Brites, Trigo et al. 2011). This effect of a lowered insulin and glucose 
response was not observed in our mice.  
 Lowered cholesterol levels in blood due to RS are thought to be caused by 
synthesis of SCFAs, which can lower cholesterol synthesis in the liver. (Vanhoof and 
De Schrijver 1998, Fernandez, Roy et al. 2000). The primary SCFA associated with 
these lowered levels of lipids is propionate. Propionate is metabolized in the liver to 
create acetyl-CoA, which would attenuate cholesterol and fatty acid synthesis in the 
liver, as well as increasing HDL cholesterol production (Soral-Smietana and 
Wronkowska 2004). We did not observe a lowered triglyceride concentration or 
total cholesterol in mice fed the RS4 supplemented diet, nor did we observe a higher 
HDL cholesterol concentration in the RS4 fed mice.  
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Histopathology 
 We predicted that the C. rodentium infection would cause severe 
inflammation in the lining of the colon. We hypothesized that the mice on the RS4 
diet would have mitigation of the inflammatory responses, indicating protection 
from the resistant starch.  
 C. rodentium causes epithelial hyperplasia in the colon (Borenshtein, 
Nambiar et al. 2007). Wang et al (2006) found that in male and female Swiss-
Webster mice, gland hyperplasia was at its maximum at 12 days post inoculation of 
C. rodentium (Wang, Xiang et al. 2006). In our study, we found that there was a 
significant increase in hyperplasia in infected mice. At p<0.05, there was not a 
significant decrease in hyperplasia score for infected mice fed the RS4 diet 
compared to the uninfected mice. However, when p<0.10, the RS4 fed infected mice 
displayed a significantly lower hyperplasia score compared to the control diet fed 
infected mice. Although not significantly similar to the hyperplasia score uninfected 
mice, the lowered hyperplasia score indicates a partial protective effect of the 
resistant starch on hyper proliferation of cells associated with inflammation. 
 Other histological changes associated with Citrobacter rodentium include the 
following: goblet cell loss, and ulceration (Borenshtein, Nambiar et al. 2007). 
Higgins et al (1999) found that by day 6 post inoculation with C. rodentium, female 
Swiss NIH and C3H mice began to experience a significant thickening of the colon 
(Higgins, Frankel et al. 1999).  We predicted that mice infected with C. rodentium 
would exhibit these responses, but mice fed the RS4 diet would have a lessened 
inflammatory response. In our study, mice infected with C. rodentium displayed a 
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significantly higher score for ulceration and goblet cell loss. However, at p<0.05, 
there was no significant difference observed between the RS4 diet and control 
starch diet in infected mice. At p<0.10, scores for ulceration and goblet cell loss were 
significantly lowered in RS4 fed infected mice compared to control starch fed mice. 
This potentially shows a protective effect of the resistant starch treatment to the 
inflammatory effects brought on by C. rodentium. The inflammation score for C. 
rodentium infected mice did increase compared to uninfected mice. However, the 
scores for inflammation between both treatments on the RS4 diet were not 
significantly different. This supports the conclusion of partial protection by the 
resistant starch diet on the effects created by C. rodentium.  
 The lessened severity of inflammatory responses due to the RS diet could be 
attributed to the indigestibility of the starch, and its passage to the large intestine. 
The fermentation of resistant starch in the large intestine produced short chain fatty 
acids. An important SCFA produced is butyrate. The production of this butyrate 
stimulates the function of enterocytes in the gut, which use it as an energy source. 
This increases the cells capability of overcoming the disruption of barrier function 
caused by pathogens like C. rodentium (Jacobasch, Schmiedl et al. 1999). The ability 
of the RS4 to be fermented in the large intestine to a higher degree than the control 
starch lead to a higher SCFA production in the gut. This opens up the potential of 
using type-4 resistant starch as a treatment option to decrease or protect against 
inflammation associated with diseases like colitis.  
 We observed a significant improvement of inflammatory responses including 
gland hyperplasia, ulceration, and goblet cell loss when p<0.10. This improvement, 
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although still significantly lower than the uninfected mice, suggests a partial 
protection by RS4 against the inflammation associated with the Citrobacter 
rodentium model. The partial protection of the RS introduces RS4 as a protective 
treatment for inflammation in colitis.  
 
Limitations 
 This study was a short-term study, only 14 days. Although significant 
findings were observed, a longer study may have revealed more benefits to the RS 
diet. C. Rodentium is a self-limiting infection, and lasts only 3-4 weeks before being 
cleared (Borenshtein, McBee et al. 2008). This would not allow for a longer study, 
due to some of the decline in inflammation and increase in stool consistency being 
caused by the clearance of the infection. 
 The correlation between SCFA production and mitigation of diarrhea was not 
able to be determined in this study. A further study of the mitigating effects of 
diarrhea due to RS consumption and its relation to fecal SCFA or SCFA production in 
the gut would be necessary to confirm this notion.  
 
General Conclusions 
 Our results indicate that a diet supplemented with RS4 can lessen the 
severity of diarrhea caused by the Citrobacter rodentium A/E pathogen. Future 
research should be considered to probe the mechanism of type-4 resistant starch on 
gut barrier function, leading to this mitigation of diarrhea. Our results also suggest a 
partial protection by RS4 against inflammatory responses associated with the 
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Citrobacter rodentium pathogen. Additional research investigating the mechanisms 
of RS4 on inflammatory responses is necessary as well. The outcome of additional 
research could create a RS supplemented food product used as an anti-diarrheal and 
anti-inflammatory dietary treatment. 
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